Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

    Summary
    EudraCT number
    2016-004390-41
    Trial protocol
    GB   DE   NL   BE  
    Global end of trial date
    21 Mar 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    04 Apr 2025
    First version publication date
    04 Apr 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    BO42863
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03037385
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    F. Hoffmann-La Roche AG
    Sponsor organisation address
    Grenzacherstrasse, 124, Basel, Switzerland, CH-4058
    Public contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Scientific contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    21 Mar 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    21 Mar 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), rearranged during transfection (RET)-altered NSCLC and other RET-altered solid tumors.
    Protection of trial subjects
    All study participants were required to read and sign an Informed Consent Form (ICF).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    17 Mar 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 2
    Country: Number of subjects enrolled
    China: 111
    Country: Number of subjects enrolled
    Germany: 39
    Country: Number of subjects enrolled
    Spain: 37
    Country: Number of subjects enrolled
    France: 45
    Country: Number of subjects enrolled
    United Kingdom: 13
    Country: Number of subjects enrolled
    Italy: 40
    Country: Number of subjects enrolled
    Korea, Republic of: 59
    Country: Number of subjects enrolled
    Netherlands: 15
    Country: Number of subjects enrolled
    Singapore: 12
    Country: Number of subjects enrolled
    Taiwan: 10
    Country: Number of subjects enrolled
    United States: 207
    Worldwide total number of subjects
    590
    EEA total number of subjects
    178
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    405
    From 65 to 84 years
    180
    85 years and over
    5

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    A total of 590 participants with rearranged during transfection (RET) fusion-positive NSCLC, RET mutation-positive MTC (also known as RET-mutant MTC), RET fusion-positive thyroid cancer (TC) and other advanced solid tumors took part in the study at 74 investigative sites across 13 countries from 17 March 2017 to 21 March 2024.

    Pre-assignment
    Screening details
    The study was divided into two phases. In Phase 1 (Dose Escalation), participants received pralsetinib at varying doses. In Phase 2 (Dose Expansion), participants received fixed dose of pralsetinib.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Phase I: Pralsetinib 30 mg
    Arm description
    Participants received pralsetinib 30 milligrams (mg), orally, once a day (QD) until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 30 mg, orally was administered to participants, QD.

    Arm title
    Phase I: Pralsetinib 60 mg
    Arm description
    Participants received pralsetinib 60 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 60 mg, orally was administered to participants, QD.

    Arm title
    Phase I: Pralsetinib 100 mg
    Arm description
    Participants received pralsetinib 100 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 100 mg, orally was administered to participants, QD.

    Arm title
    Phase I: Pralsetinib 200 mg
    Arm description
    Participants received pralsetinib 200 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 200 mg, orally was administered to participants, QD.

    Arm title
    Phase I: Pralsetinib 300 mg
    Arm description
    Participants received pralsetinib 300 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 300 mg, orally was administered to participants, QD.

    Arm title
    Phase I: Pralsetinib 400 mg
    Arm description
    Participants received pralsetinib 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 400 mg, orally was administered to participants, QD.

    Arm title
    Phase I: Pralsetinib 600 mg
    Arm description
    Participants received pralsetinib 600 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 600 mg, orally was administered to participants, QD.

    Arm title
    Phase I: Pralsetinib 100/100 mg
    Arm description
    Participants received pralsetinib 100 mg, orally, twice a day (BID) until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 100 mg, orally was administered to participants, BID.

    Arm title
    Phase I: Pralsetinib 200/100 mg
    Arm description
    Participants received pralsetinib 200 mg in the morning and then 100 mg in the evening orally until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet, Tablet
    Routes of administration
    Oral use, Oral use
    Dosage and administration details
    Pralsetinib, 200 mg in the morning and then 100 mg in the evening was administered to participants, orally.

    Arm title
    Phase II: Pralsetinib 400 mg
    Arm description
    Participants with advanced NSCLC, advanced non-resectable TC and other advanced non-resectable solid tumors with various RET-alterations were enrolled in this arm to receive pralsetinib, 400 mg, QD until discontinuation due to toxicity, disease progression, or other reasons.
    Arm type
    Experimental

    Investigational medicinal product name
    Pralsetinib
    Investigational medicinal product code
    RO7499790
    Other name
    BLU-667
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Pralsetinib, 400 mg, orally was administered to participants, QD.

    Number of subjects in period 1
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg Phase II: Pralsetinib 400 mg
    Started
    2
    6
    5
    13
    11
    12
    4
    6
    3
    528
    Completed
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Not completed
    2
    6
    5
    13
    11
    12
    4
    6
    3
    528
         Initiation Of Another Therapy
    1
    -
    -
    -
    -
    -
    -
    1
    -
    2
         Consent withdrawn by subject
    -
    -
    1
    2
    1
    3
    -
    -
    -
    52
         Physician decision
    -
    -
    -
    -
    -
    -
    -
    -
    -
    1
         Adverse Event
    -
    -
    1
    -
    -
    -
    -
    -
    -
    6
         Death
    1
    4
    2
    2
    5
    2
    1
    5
    2
    240
         Reason Not Specified
    -
    1
    -
    4
    3
    6
    2
    -
    1
    181
         Progressive Disease
    -
    1
    1
    5
    2
    -
    1
    -
    -
    30
         Lost to follow-up
    -
    -
    -
    -
    -
    1
    -
    -
    -
    16

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Phase I: Pralsetinib 30 mg
    Reporting group description
    Participants received pralsetinib 30 milligrams (mg), orally, once a day (QD) until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 60 mg
    Reporting group description
    Participants received pralsetinib 60 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 100 mg
    Reporting group description
    Participants received pralsetinib 100 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 200 mg
    Reporting group description
    Participants received pralsetinib 200 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 300 mg
    Reporting group description
    Participants received pralsetinib 300 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 400 mg
    Reporting group description
    Participants received pralsetinib 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 600 mg
    Reporting group description
    Participants received pralsetinib 600 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 100/100 mg
    Reporting group description
    Participants received pralsetinib 100 mg, orally, twice a day (BID) until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 200/100 mg
    Reporting group description
    Participants received pralsetinib 200 mg in the morning and then 100 mg in the evening orally until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase II: Pralsetinib 400 mg
    Reporting group description
    Participants with advanced NSCLC, advanced non-resectable TC and other advanced non-resectable solid tumors with various RET-alterations were enrolled in this arm to receive pralsetinib, 400 mg, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg Phase II: Pralsetinib 400 mg Total
    Number of subjects
    2 6 5 13 11 12 4 6 3 528 590
    Age categorical
    Units: Subjects
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    54.5 ( 9.2 ) 49.5 ( 18.0 ) 51.2 ( 13.2 ) 53.8 ( 13.6 ) 60.6 ( 11.0 ) 49.2 ( 17.8 ) 59.5 ( 9.1 ) 63.7 ( 10.7 ) 60.0 ( 21.9 ) 57.7 ( 12.6 ) -
    Sex: Female, Male
    Units: participants
        Female
    1 3 4 5 4 3 3 2 1 257 283
        Male
    1 3 1 8 7 9 1 4 2 271 307
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    2 2 1 1 0 3 0 0 0 19 28
        Not Hispanic or Latino
    0 4 4 12 11 9 4 4 3 465 516
        Unknown or Not Reported
    0 0 0 0 0 0 0 2 0 44 46
    Race/Ethnicity, Customized
    Units: Subjects
        Asian
    0 1 2 0 0 2 0 1 0 203 209
        Native Hawaiian or Other Pacific Islander
    0 0 0 0 0 0 0 0 0 2 2
        Black or African American
    0 0 0 1 0 1 0 0 0 4 6
        White
    0 3 2 11 11 9 4 4 3 284 331
        Other
    0 0 0 0 0 0 0 0 0 3 3
        Unknown or Not Reported
    2 2 1 1 0 0 0 1 0 32 39

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Phase I: Pralsetinib 30 mg
    Reporting group description
    Participants received pralsetinib 30 milligrams (mg), orally, once a day (QD) until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 60 mg
    Reporting group description
    Participants received pralsetinib 60 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 100 mg
    Reporting group description
    Participants received pralsetinib 100 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 200 mg
    Reporting group description
    Participants received pralsetinib 200 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 300 mg
    Reporting group description
    Participants received pralsetinib 300 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 400 mg
    Reporting group description
    Participants received pralsetinib 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 600 mg
    Reporting group description
    Participants received pralsetinib 600 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 100/100 mg
    Reporting group description
    Participants received pralsetinib 100 mg, orally, twice a day (BID) until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase I: Pralsetinib 200/100 mg
    Reporting group description
    Participants received pralsetinib 200 mg in the morning and then 100 mg in the evening orally until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Phase II: Pralsetinib 400 mg
    Reporting group description
    Participants with advanced NSCLC, advanced non-resectable TC and other advanced non-resectable solid tumors with various RET-alterations were enrolled in this arm to receive pralsetinib, 400 mg, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    Phase 1: All Participants QD
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants received pralsetinib at varying doses at a QD schedule until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    Pralsetinib ≤ 300 mg QD
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Participants received pralsetinib, 300 mg or less, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    Pralsetinib 400 mg QD
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Participants received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    Pralsetinib BID Dosing Schedule
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Participants received pralsetinib, 100 mg, orally, BID or 200 mg in the morning and then 100 mg in the evening, orally, until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET- fusion Positive NSCLC With Prior Platinum Treatment
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-fusion positive NSCLC previously treated with platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-fusion Positive NSCLC With Non-platinum Systemic Treatment
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-fusion positive NSCLC previously treated with non-platinum or systemic therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-fusion positive NSCLC not previously treated with systemic or platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET- mutation positive MTC previously treated with either cabozantinib and/or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-mutation MTC With No Cabozantinib/Vandetanib Treatment
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET- mutation positive MTC not previously treated with cabozantinib or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-fusion Positive TC
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-fusion positive TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-fusion Positive Solid Tumors Other Than NSCLC and TC
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had other RET-positive solid tumors other than NSCLC and TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-altered Solid Tumors Previously Treated With RET Inhibitor
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-altered (fusion or mutation) solid tumors previously treated with a selective RET tyrosine kinase inhibitor (TKI) received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET-mutation Positive Tumors Other Than MTC
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-mutation positive solid tumors received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    RET- fusion Positive NSCLC Participants
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-fusion positive NSCLC received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.

    Subject analysis set title
    Tumor-agnostic Participants
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-fusion positive NSCLC or TC, or RET-mutation positive MTC, each with different genetic mutations received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.

    Subject analysis set title
    RET-altered Solid Tumors Participants
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-altered (fusion or mutation) solid tumors previously treated with a selective RET TKI received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.

    Subject analysis set title
    RET-mutation Positive Tumors other than MTC Participants
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants who had RET-mutation positive solid tumors received Pralsetinib 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.

    Subject analysis set title
    Phase I: Pralsetinib 200/100 mg
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Participants received pralsetinib 200 mg in the morning and then 100 mg in the evening orally until discontinuation due to toxicity, disease progression, or other reasons.

    Subject analysis set title
    Pralsetinib All Doses
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    Participants received pralsetinib at varying doses at the QD and BID schedule until discontinuation due to toxicity, disease progression, or other reasons.

    Primary: Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib

    Close Top of page
    End point title
    Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib [1]
    End point description
    MTD was defined as the highest tolerated dose of pralsetinib without causing dose limiting toxicities (DLTs). DLT was defined as any Grade ≥3 adverse event (AE) occurring during Cycle 1 during Phase 1 (dose escalation) that is not clearly caused by something other than pralsetinib. RP2D was defined as the highest dose with acceptable toxicity as determined from dose-escalation phase. Dose-determining population included all participants in the dose-escalation part who have received ≥75% (21 days) of the study drug and completed safety evaluations through Cycle 1 Day 28 or experienced a DLT.
    End point type
    Primary
    End point timeframe
    Up to approximately 30.8 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistics was planned for this endpoint.
    End point values
    Phase 1: All Participants QD
    Number of subjects analysed
    51
    Units: mg
        MTD
    400
        RP2D
    400
    No statistical analyses for this end point

    Primary: Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs)

    Close Top of page
    End point title
    Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) [2]
    End point description
    AE=any untoward medical occurrence associated with use of drug in humans, whether or not considered drug related. AE can be any unfavorable & unintended sign, symptom/disease temporally associated with use of drug, without any judgment about causality. SAE=any significant hazard, contraindication, side effect that is fatal/life-threatening, requires hospitalization/prolongation of existing hospitalization, results in persistent/significant disability, is congenital anomaly/birth defect, is medically significant/requires intervention to prevent the outcomes listed above. Safety Population included all participants who have received at least 1 dose of the study drug regardless of starting dose levels. As pre-specified in the SAP, safety data was to be analyzed and reported as per the pre-planned grouped dose level II (SAP section 3.6.5.2). Hence, per dose safety data is not presented for this study.
    End point type
    Primary
    End point timeframe
    From Cycle 1 Day 1 up to 30 days after the final dose of study drug (up to approximately 6.7 years)
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistics was planned for this endpoint.
    End point values
    Pralsetinib ≤ 300 mg QD Pralsetinib 400 mg QD Pralsetinib BID Dosing Schedule Pralsetinib All Doses
    Number of subjects analysed
    37
    540
    9
    590
    Units: percentage of participants
    number (not applicable)
        AEs
    37
    540
    9
    590
        SAEs
    26
    381
    7
    416
    No statistical analyses for this end point

    Primary: Phase 2: Overall Response Rate (ORR)

    Close Top of page
    End point title
    Phase 2: Overall Response Rate (ORR) [3]
    End point description
    ORR=percentage of participants with a confirmed complete response (CR)/partial response (PR) for at least 2 assessments with at least 28 days apart & no disease progression (PD) in between. Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), CR=disappearance of all target lesions/any pathological lymph nodes (whether target/non-target) having a reduction in short axis to <10 millimeters(mm). PR=at least 30% decrease in sum of diameters (SOD) of all target lesions, taking as reference baseline SOD, in absence of CR. PD=at least a 20% increase in SOD of target lesions, taking as reference smallest SOD on study (including baseline). RET-altered measurable disease population=participants in efficacy population who had measurable (target) disease per RECIST v1.1 at baseline according to blinded central review (BICR) &sufficient evidence of RET alteration. As prespecified in SAP, Phase 1 participants treated at 400 mg QD were included in Phase 2 efficacy analysis.
    End point type
    Primary
    End point timeframe
    Up to approximately 79.8 months
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No formal statistics was planned for this endpoint.
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment RET-fusion Positive TC RET-fusion Positive Solid Tumors Other Than NSCLC and TC RET-altered Solid Tumors Previously Treated With RET Inhibitor RET-mutation Positive Tumors Other Than MTC
    Number of subjects analysed
    130
    23
    106
    60
    72
    27
    28
    21
    13
    Units: percentage of participants
        number (confidence interval 95%)
    63.1 (54.2 to 71.4)
    73.9 (51.6 to 89.8)
    78.3 (69.2 to 85.7)
    56.7 (43.2 to 69.4)
    77.8 (66.4 to 86.7)
    85.2 (66.3 to 95.8)
    46.4 (27.5 to 66.1)
    19.0 (5.4 to 41.9)
    7.7 (0.99 to 36.0)
    No statistical analyses for this end point

    Secondary: Phase 1: ORR

    Close Top of page
    End point title
    Phase 1: ORR [4]
    End point description
    ORR was defined as percentage of participants with a confirmed CR or PR for at least two assessments with at least 28 days apart and no PD in between. Per RECIST v1.1, CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). ORR and its two-sided 95% CI, based on the exact binomial distribution (Clopper-Pearson), was presented. Efficacy population includedall participants who have been exposed to at least one dose of the study on/prior to 11 July 2019. -0.9999&9999=The lower and upper limit of 95% confidence interval (CI) was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 28 months
    Notes
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report data for Phase I of the study only. Hence, Phase II arm is not included.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    5
    13
    11
    12
    4
    5
    4
    Units: percentage of participants
        number (confidence interval 95%)
    0 (-0.9999 to 9999)
    50.0 (11.8 to 88.2)
    40.0 (5.3 to 85.3)
    38.5 (13.9 to 68.4)
    45.5 (16.7 to 76.6)
    41.7 (15.2 to 72.3)
    25.0 (0.99 to 80.6)
    80.0 (28.4 to 99.5)
    75.0 (19.4 to 99.4)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: ORR in RET-fusion Positive NSCLC Participants with Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: ORR in RET-fusion Positive NSCLC Participants with Specific RET Gene Status
    End point description
    Oncogenic RET rearrangements have been identified in 1−2% of NSCLC. These rearrangements typically produce chimeric transcripts encoding fusion protein consisting of RET kinase domain coupled to a protein with dimerization domain (eg Kinesin family member 5B(KIF5B), coiled-coil domain containing 6(CCDC6), nuclear receptor coactivator 4(NCOA4). RET genotypes determined by local testing/central analysis of circulating tumor deoxyribonucleic acid(ctDNA). ORR=% of participants with confirmed CR/PR for at least 2 assessments 28 days apart & no PD in between. CR/PR/PD: defined per RECIST as outlined in description for ORR endpoint (EP). RET-altered measurable disease (RAMD) population. As prespecified in SAP, Phase 1 participants treated at 400 mg are pooled with Phase 2 participants for efficacy analysis. n=number of participants with specified mutation. 9999=95% CI was not estimable due to insufficient number of participants with events. 99999=no participants had the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    130
    23
    106
    Units: percentage of participants
    number (confidence interval 95%)
        KIF5B(n=91,17,76)
    63.7 (53.0 to 73.6)
    82.4 (56.6 to 96.2)
    78.9 (68.1 to 87.5)
        CCDC6(n=25,4,19)
    68.0 (46.5 to 85.1)
    75.0 (19.4 to 99.4)
    84.2 (60.4 to 96.6)
        NCOA4(n=1,0,0)
    100 (2.5 to 100)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        Other(n=13,2,11)
    46.2 (19.2 to 74.9)
    0 (-9999 to 9999)
    63.6 (30.8 to 89.1)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: ORR in RET-mutation MTC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: ORR in RET-mutation MTC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in MTC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., M918T, cysteine rich domain, V804X). RET genotypes were determined by local testing and/or central analysis of ctDNA. ORR was assessed in participants having specific RET rearrangements. ORR was defined as the percentage of participants with a confirmed CR or PR for at least 2 assessments with at least 28 days apart and no PD in between. CR, PR, and PD were defined per RECIST as outlined in the description for ORR EP. RAMD population. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with the specified mutation. -0.9999&9999=Since only 1 participant was analyzed upper and lower limit of 95% CI was not evaluable..
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment
    Number of subjects analysed
    60
    72
    Units: percentage of participants
    number (confidence interval 95%)
        M918T (n=41,43)
    53.7 (37.4 to 69.3)
    74.4 (58.8 to 86.5)
        Cysteine Rich Domain(n=13,25)
    46.2 (19.2 to 74.9)
    88.0 (68.8 to 97.5)
        V804X(n=2,1)
    100 (15.8 to 100)
    0 (-0.9999 to 9999)
        Other(n=4,3)
    100 (39.8 to 100)
    66.7 (9.4 to 99.2)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: ORR in RET-fusion Positive TC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: ORR in RET-fusion Positive TC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in both MTC and differentiated TC (DTC). These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., KIF5B, CCDC6, NCOA4). RET genotypes were determined by local testing and/or central analysis of ctDNA. ORR was assessed in participants having specific RET rearrangements. ORR was defined as the percentage of participants with a confirmed CR or PR for at least 2 assessments with at least 28 days apart and no PD in between. CR, PR, and PD were defined per RECIST as outlined in the description for ORR EP. RAMD population. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with the specified mutation. 9999=no participants exhibited the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-fusion Positive TC
    Number of subjects analysed
    27
    Units: percentage of participants
    number (confidence interval 95%)
        KIF5B(n=0)
    9999 (9999 to 9999)
        CCDC6(n=17)
    82.4 (56.6 to 96.2)
        NCOA4(n=6)
    100 (54.1 to 100)
        Other(n=4)
    75.0 (19.4 to 99.4)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: Clinical Benefit Rate (CBR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: Clinical Benefit Rate (CBR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET rearrangements have been identified in 1%−2% of NSCLC. These rearrangements typically produce chimeric transcripts that encode fusion protein consisting of RET kinase domain coupled to a protein with a dimerization domain. RET genotypes were determined by local testing/central analysis of ctDNA. CBR was defined as percentage of participants with confirmed CR, PR or stable disease (SD) which has been lasting at least 16 weeks from 1st dose date. CR, PR & PD were defined per RECIST as outlined in description for ORR EP. SD=neither sufficient shrinkage to qualify for CR/PR nor sufficient increase to qualify for PD. RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with specified mutation. 9999=95% CI was not estimable due to insufficient number of participants with events. 99999=no participants exhibited the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    130
    23
    106
    Units: percentage of participants
    number (confidence interval 95%)
        KIF5B(n=91,17,76)
    76.9 (66.9 to 85.1)
    88.2 (63.6 to 98.5)
    81.6 (71.0 to 89.5)
        CCDC6(n=25,4,19)
    76.0 (54.9 to 90.6)
    75.0 (19.4 to 99.4)
    84.2 (60.4 to 96.6)
        NCOA4(n=1,0,0)
    100 (2.5 to 100)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        Other(13,2,11)
    53.8 (25.1 to 80.8)
    0 (-9999 to 9999)
    63.6 (30.8 to 89.1)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: CBR in RET-mutation MTC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: CBR in RET-mutation MTC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in MTC. These rearrangements typically produce chimeric transcripts that encode fusion protein consisting of RET kinase domain coupled to a protein with a dimerization domain(e.g. M918T, cysteine rich domain, V804X). RET genotypes were determined by local testing/central analysis of ctDNA. CBR was defined aspercentage of participants with confirmed CR, PR or SD which has been lasting at least 16 weeks from first dose date. CR and PR were defined per RECIST as outlined in description for EP 3. SD was defined asneither sufficient shrinkage to qualify for CR/PR nor sufficient increase to qualify for PD. PD was defined asat least a 20% increase in SOD of target lesions, taking as reference smallest SOD on study (including baseline). RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment
    Number of subjects analysed
    60
    72
    Units: percentage of participants
    number (confidence interval 95%)
        M918T(n=41,43)
    78.0 (62.4 to 89.4)
    86.0 (72.1 to 94.7)
        Cysteine Rich Domain(n=13,25)
    76.9 (46.2 to 95.0)
    96.0 (79.6 to 99.9)
        V804X(n=2,1)
    100 (15.8 to 100)
    100 (2.5 to 100)
        Other(n=4,3)
    100 (39.8 to 100)
    100 (29.2 to 100)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: CBR in RET-fusion Positive TC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: CBR in RET-fusion Positive TC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in both MTC & DTC. These rearrangements typically produce chimeric transcripts that encode fusion protein consisting of RET kinase domain coupled to protein with a dimerization domain(e.g., KIF5B, CCDC6, NCOA4). RET genotypes were determined by local testing/central analysis of ctDNA. CBR=percentage of participants with a confirmed CR/PR/SD which has been lasting at least 16 weeks from first dose date. CR & PR were defined per RECIST as outlined in description for ORR EP. SD=neither sufficient shrinkage to qualify for CR/PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with specified mutation. 9999=no participants exhibited the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-fusion Positive TC
    Number of subjects analysed
    27
    Units: percentage of participants
    number (confidence interval 95%)
        KIF5B(n=0)
    9999 (9999 to 9999)
        CCDC6(n=17)
    82.4 (56.6 to 96.2)
        NCOA4(n=6)
    100 (54.1 to 100)
        Other(n=4)
    75.0 (19.4 to 99.4)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: Disease Control Rate (DCR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: Disease Control Rate (DCR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET rearrangements have been identified in 1-2% of NSCLC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., KIF5B, CCDC6, NCOA4). RET genotypes were determined by local testing/central analysis of ctDNA. DCR was assessed in participants having specific RET rearrangements. DCR=percentage of participants with confirmed CR/PR/SD. CR & PR were defined per RECIST as outlined in the description for ORR EP. SD=neither sufficient shrinkage to qualify for CR/PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). RAMD population. As per SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with specified mutation. 9999=no participants exhibited the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    130
    23
    106
    Units: percentage of participants
    number (confidence interval 95%)
        KIF5B(n=91,17,76)
    93.4 (86.2 to 97.5)
    94.1 (71.3 to 99.9)
    88.2 (78.7 to 94.4)
        CCDC6(n=25,4,19)
    88.0 (68.8 to 97.5)
    100 (39.8 to 100)
    89.5 (66.9 to 98.7)
        NCOA4(n=1,0,0)
    100 (2.5 to 100)
    9999 (9999 to 9999)
    9999 (9999 to 9999)
        Other(n=13,2,11)
    84.6 (54.6 to 98.1)
    50.0 (1.3 to 98.7)
    100 (71.5 to 100)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: DCR in RET-mutation MTC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: DCR in RET-mutation MTC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in MTC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., M918T, cysteine rich domain, V804X). RET genotypes were determined by local testing/central analysis of ctDNA. DCR was assessed in participants having specific RET rearrangements. DCR=percentage of participants with a confirmed CR/PR/SD. CR & PR were defined per RECIST as outlined in the description for ORR EP. SD=neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment
    Number of subjects analysed
    60
    72
    Units: percentage of participants
    number (confidence interval 95%)
        M918T(n=41,43)
    95.1 (83.5 to 99.4)
    90.7 (77.9 to 97.4)
        Cysteine Rich Domain(n=13,25)
    92.3 (64.0 to 99.8)
    96.0 (79.6 to 99.9)
        V804X(n=2,1)
    100 (15.8 to 100)
    100 (2.5 to 100)
        Other(n=4,3)
    100 (39.8 to 100)
    100 (29.2 to 100)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: DCR in RET-fusion Positive TC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: DCR in RET-fusion Positive TC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in both MTC & DTC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of RET kinase domain coupled to protein with a dimerization domain(e.g., KIF5B, CCDC6, NCOA4). RET genotypes were determined by local testing/central analysis of ctDNA. DCR was assessed in participants having specific RET rearrangements. DCR=percentage of participants with confirmed CR/PR/SD. CR & PR were defined per RECIST as outlined in the description for ORR EP. SD=neither sufficient shrinkage to qualify for CR/PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). RAMD population. As per SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. n=number of participants with specified mutation. 9999=no participants exhibited the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-fusion Positive TC
    Number of subjects analysed
    27
    Units: percentage of participants
    number (confidence interval 95%)
        KIF5B(n=0)
    9999 (9999 to 9999)
        CCDC6(n=17)
    94.1 (71.3 to 99.9)
        NCOA4(n=6)
    100 (54.1 to 100)
        Other(n=4)
    100 (39.8 to 100)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: Duration of Response (DOR) in RET-mutation MTC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: Duration of Response (DOR) in RET-mutation MTC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in MTC. RET genotypes were determined by local testing/central analysis of ctDNA. DOR=time from first documented CR/PR to date of first documented PD/death due to any cause, whichever occurs first. CR, PR and PD were defined per RECIST as outlined in description for ORR EP. DOR was analyzed using the Kaplan-Meier (KM) method. RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Participants with a response of CR/PR were analyzed. n=number of participants with specified mutation. 9999=upper limit of 95% CI was not estimable due to insufficient number of participants with events. 99999=median & upper limit of 95% CI was not estimable due to insufficient number of participants with events. 999999=median & 95% CI was not estimable due to insufficient number of participants with events. 9999999=no participants exhibited the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment
    Number of subjects analysed
    34
    56
    Units: months
    median (confidence interval 95%)
        M918T(n=22,32)
    18.4 (15.1 to 25.8)
    51.8 (40.0 to 9999)
        Cysteine Rich Domain(n=6,22)
    29.5 (8.9 to 9999)
    36.8 (23.1 to 9999)
        V804X(n=2,0)
    21.8 (14.2 to 29.4)
    9999999 (9999999 to 9999999)
        Other(n=4,2)
    99999 (14.5 to 99999)
    999999 (999999 to 999999)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: DOR in RET-mutation NSCLC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: DOR in RET-mutation NSCLC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET rearrangements have been identified in 1%−2% of NSCLC. RET genotypes were determined by local testing and/or central analysis of ctDNA. DOR=time from first documented CR/PR to date of first documented PD/death due to any cause, whichever occurs first. CR, PR and PD were defined per RECIST as outlined in description for ORR EP. DOR was analyzed using the KM method. RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Participants with a response of CR/PR were analyzed. n=number of participants with specified mutation. 9999=upper limit of 95% CI was not estimable due to insufficient number of participants with events. 0.999=lower limit of 95% CI was not estimable due to insufficient number of participants with events. 99999=no participants exhibited the specified mutation.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    82
    17
    83
    Units: months
    median (confidence interval 95%)
        KIF5B (n=58,14,60)
    15.1 (8.8 to 34.2)
    21.5 (9.3 to 9999)
    9.2 (7.4 to 13.4)
        CCDC6 (n=17,34,16)
    46.7 (33.7 to 9999)
    29.6 (11.3 to 47.9)
    0.999 (-9999 to 9999)
        NCOA4 (n=1,0,0)
    0.999 (-9999 to 9999)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
        Other (n=6,0,7)
    35.2 (10.6 to 9999)
    99999 (99999 to 99999)
    41.2 (27.9 to 9999)
    No statistical analyses for this end point

    Secondary: Phase 1 and Phase 2: DOR in RET-fusion Positive TC Participants With Specific RET Gene Status

    Close Top of page
    End point title
    Phase 1 and Phase 2: DOR in RET-fusion Positive TC Participants With Specific RET Gene Status
    End point description
    Oncogenic RET activation has been implicated as a driver in MTC. RET genotypes were determined by local testing/central analysis of ctDNA. DOR=time from first documented CR or PR to date of first documented PD or death due to any cause, whichever occurs first. CR and PR were defined per RECIST v1.1 as outlined in description for ORR EP. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD on study (including baseline). DOR was analyzed using the KM method. RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Participants who had a response of CR/PR were analyzed in this outcome measure. n=number of participants with specified mutation. 9999=upper limit of 95% CI was not estimable due to insufficient number of participants with events. 99999=median and upper limit of 95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET-fusion Positive TC
    Number of subjects analysed
    23
    Units: months
    median (confidence interval 95%)
        CCDC6(n=14)
    99999 (11.2 to 99999)
        NCOA4(n=6)
    15.2 (6.9 to 9999)
        Other(n=3)
    99999 (23.6 to 99999)
    No statistical analyses for this end point

    Secondary: Phase 2: DOR

    Close Top of page
    End point title
    Phase 2: DOR
    End point description
    DOR was defined as time from first documented response (CR/PR) to the date of first documented PD or death due to any cause, whichever occurs first. CR and PR were defined as per RECIST v1.1 as outlined in description for ORR endpoint. PD was defined asat least a 20% increase in SOD of target lesions, taking as reference smallest SOD on study (including baseline). DOR was analyzed using KM methods. RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Participants who had a response of CR/PR were analyzed in this endpoint. 9999=upper limit of 95% CI was not estimable due to insufficient number of participants with events. 999 =median & upper limit of 95% CI was not estimable due to insufficient number of participants with events. 0.999 and 999999=95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment RET-fusion Positive TC RET-fusion Positive Solid Tumors Other Than NSCLC and TC RET-altered Solid Tumors Previously Treated With RET Inhibitor RET-mutation Positive Tumors Other Than MTC
    Number of subjects analysed
    82
    17
    83
    34
    56
    23
    13
    4
    1
    Units: months
        median (confidence interval 95%)
    31.8 (15.1 to 40.4)
    22.6 (11.1 to 47.9)
    13.4 (9.4 to 21.7)
    21.7 (15.1 to 34.8)
    51.8 (36.8 to 9999)
    999 (12.9 to 999)
    11.1 (5.5 to 25.1)
    99999 (6.0 to 99999)
    5.5 (0.999 to 999999)
    No statistical analyses for this end point

    Secondary: Phase 2: CBR

    Close Top of page
    End point title
    Phase 2: CBR
    End point description
    CBR was defined as the percentage of participants with CR or PR, or SD which has been lasting at least 16 weeks (i.e. 4 cycles if 28 days are in one cycle) from the first dose date. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). CBR and its two-sided 95% CI, which is based on the exact binomial distribution (Clopper-Pearson), were presented. RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment RET-fusion Positive TC RET-fusion Positive Solid Tumors Other Than NSCLC and TC RET-altered Solid Tumors Previously Treated With RET Inhibitor RET-mutation Positive Tumors Other Than MTC
    Number of subjects analysed
    130
    23
    106
    60
    72
    27
    28
    21
    13
    Units: percentage of participants
        number (confidence interval 95%)
    74.6 (66.2 to 81.8)
    78.3 (56.3 to 92.5)
    80.2 (71.3 to 87.3)
    80.0 (67.7 to 89.2)
    90.3 (81.0 to 96.0)
    85.2 (66.3 to 95.8)
    60.7 (40.6 to 78.5)
    28.6 (11.3 to 52.2)
    23.1 (5.0 to 53.8)
    No statistical analyses for this end point

    Secondary: Phase 2: DCR

    Close Top of page
    End point title
    Phase 2: DCR
    End point description
    DCR was defined as the percentage of participants with a confirmed CR/PR, or SD, per RECIST v1.1. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). DCR and its two-sided 95% CI, which is based on the exact binomial distribution (Clopper-Pearson), were presented. RAMD population. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment RET-fusion Positive TC RET-fusion Positive Solid Tumors Other Than NSCLC and TC RET-altered Solid Tumors Previously Treated With RET Inhibitor RET-mutation Positive Tumors Other Than MTC
    Number of subjects analysed
    130
    23
    106
    60
    72
    27
    28
    21
    13
    Units: percentage of participants
        number (confidence interval 95%)
    91.5 (85.4 to 95.7)
    91.3 (72.0 to 98.9)
    89.6 (82.2 to 94.7)
    95.0 (86.1 to 99.0)
    93.1 (84.5 to 97.7)
    96.3 (81.0 to 99.9)
    75.0 (55.1 to 89.3)
    42.9 (21.8 to 66.0)
    69.2 (38.6 to 90.9)
    No statistical analyses for this end point

    Secondary: Phase 2: Progression-free Survival (PFS)

    Close Top of page
    End point title
    Phase 2: Progression-free Survival (PFS)
    End point description
    PFS was defined as the time from the first dose of pralsetinib to the date of first documented PD or death due to any cause, whichever occurred first. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). PFS was analyzed using KM methods. Efficacy population included all participants who have been exposed to at least one dose of the study drug at the RP2D. As pre-specified in the SAP, PFS was to be assessed in participants with RET-fusion positive NSCLC, RET-mutation MTC, RET-fusion TC, and RET-fusion solid tumors other than NSCLC and TC. Hence, only the data for these arms is presented here. Number analyzed is the number of participants with data available for analysis. 9999=upper limit of 95% CI was not estimable due to insufficient number of participants with events. 99999=median & upper limit of 95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 7 years
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment RET-fusion Positive TC RET-fusion Positive Solid Tumors Other Than NSCLC and TC
    Number of subjects analysed
    141
    24
    116
    67
    78
    31
    28
    Units: months
        median (confidence interval 95%)
    16.4 (11.4 to 23.5)
    13.0 (9.3 to 35.1)
    12.1 (9.2 to 16.6)
    24.9 (19.9 to 35.0)
    55.3 (37.2 to 9999)
    99999 (14.7 to 99999)
    7.0 (3.9 to 12.8)
    No statistical analyses for this end point

    Secondary: Phase 2: Overall Survival (OS)

    Close Top of page
    End point title
    Phase 2: Overall Survival (OS)
    End point description
    OS was defined as the time from the first dose of pralsetinib to the date of death due to any causes. Efficacy population included all participants who have been exposed to at least one dose of the study drug at the RP2D. As pre-specified in the SAP, OS was to be assessed in participants with RET-fusion positive NSCLC, RET-mutation MTC, RET-fusion TC, and RET-fusion solid tumors other than NSCLC and TC. Hence, only the data for these arms is presented here. 9999=upper limit of 95% CI was not estimable due to insufficient number of participants with events. 99999=median and 95% CI was not estimable due to insufficient number of participants with events. 999999=median and upper limit of 95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 7 years
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment RET-mutation MTC With Cabozantinib and/or Vandetanib Treatment RET-mutation MTC With No Cabozantinib/Vandetanib Treatment RET-fusion Positive TC RET-fusion Positive Solid Tumors Other Than NSCLC and TC
    Number of subjects analysed
    141
    24
    116
    67
    78
    31
    29
    Units: months
        median (confidence interval 95%)
    39.7 (27.8 to 53.2)
    46.0 (19.1 to 62.4)
    50.1 (28.3 to 9999)
    42.2 (31.2 to 9999)
    99999 (99999 to 99999)
    999999 (19.4 to 999999)
    10.3 (6.8 to 25.2)
    No statistical analyses for this end point

    Secondary: Phase 2: Intracranial ORR in RET-fusion Positive NSCLC Central Nervous System (CNS) Metastases Participants

    Close Top of page
    End point title
    Phase 2: Intracranial ORR in RET-fusion Positive NSCLC Central Nervous System (CNS) Metastases Participants
    End point description
    ORR=percentage of participants with CR/PR for at least 2 assessments, ≥28 days apart, with no PD in between. CR=disappearance of all target CNS/brain lesions (including brainstem/cerebellum) and non-target lesions identified at baseline, with no new CNS/brain lesions. PR=at least 30% decrease in the SOD of any CNS/brain lesion identified as RECIST 1.1 target lesions, with no progression of non-target CNS/brain lesions or new lesions. PD= ≥20% increase in the SOD of target CNS/brain lesions, with a reference to the smallest sum on study, or unequivocal progression of non-target lesions or new lesions. RAMD population. As specified in the SAP, ORR was to be assessed in RET-fusion CNS metastases sub-population (participants with CNS metastases) only. Hence only NSCLC arms are presented here. Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. -0.9999 & 9999=95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    13
    1
    1
    Units: percentage of participants
        number (confidence interval 95%)
    53.8 (25.1 to 80.8)
    100 (2.5 to 100)
    0 (-0.9999 to 99999)
    No statistical analyses for this end point

    Secondary: Phase 2: Intracranial CBR in RET-fusion Positive NSCLC CNS Metastases Participants

    Close Top of page
    End point title
    Phase 2: Intracranial CBR in RET-fusion Positive NSCLC CNS Metastases Participants
    End point description
    CBR=percentage of participants with CR/PR/SD lasting ≥16 weeks from 1st dose date. CR=disappearance of all target CNS/brain lesions (including brainstem/cerebellum) & non-target lesions identified at baseline, with no new CNS/brain lesions. PR=at least 30% decrease in SOD of any CNS/brain lesion identified as RECIST 1.1 target lesions, with no progression of non-target CNS/brain lesions/new lesions. SD=neither sufficient shrinkage for PR or increase for PD for target/non-target CNS/brain lesion, with reference to smallest SOD on study. PD= ≥20% increase in SOD of target CNS/brain lesions, with a reference to smallest sum on study/unequivocal progression of non-target lesions/new lesions. As specified in SAP, CBR was in RET-fusion CNS metastases sub-population only. Hence only NSCLC arms are presented here. Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants. -0.9999 and 9999=95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    13
    1
    1
    Units: percentage of participants
        number (confidence interval 95%)
    61.5 (31.6 to 86.1)
    100 (2.5 to 100)
    0 (-0.9999 to 9999)
    No statistical analyses for this end point

    Secondary: Phase 2: Intracranial DCR in RET-fusion Positive NSCLC CNS Metastases Participants

    Close Top of page
    End point title
    Phase 2: Intracranial DCR in RET-fusion Positive NSCLC CNS Metastases Participants
    End point description
    DCR=percentage of participants with a confirmed CR/PR, or SD. CR=disappearance of all target CNS/brain lesions (including brainstem/cerebellum) & non-target lesions identified at baseline, with no new CNS/brain lesions. PR=at least 30% decrease in SOD of any CNS/brain lesion identified as RECIST 1.1 target lesions, with no progression of non-target CNS/brain lesions/new lesions. SD=neither sufficient shrinkage for PR or increase for PD for target/non-target CNS/brain lesion, with reference to smallest SOD on study. PD=≥20% increase in SOD of target CNS/brain lesions, reference to smallest sum on study/unequivocal progression of non-target lesions/new lesions. As specified in SAP, DCR was assessed in RET-fusion CNS metastases sub-population (participants with CNS metastases) only. Hence only NSCLC arms are presented. Phase 1 participants treated at 400 mg are pooled with Phase 2 participants. -0.9999&9999=95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    13
    1
    1
    Units: percentage of participants
        number (confidence interval 95%)
    76.9 (46.2 to 95.0)
    100 (2.5 to 100)
    0 (-0.9999 to 9999)
    No statistical analyses for this end point

    Secondary: Phase 2: Intracranial DOR in RET-fusion Positive NSCLC CNS Metastases Participants

    Close Top of page
    End point title
    Phase 2: Intracranial DOR in RET-fusion Positive NSCLC CNS Metastases Participants
    End point description
    DOR=time from first documented CR/PR to the date of first documented PD/death due to any cause, whichever occurs first. CR and PR were defined per RECIST as outlined in the description for endpoint 23. PD=either at least 20% increase in SOD of target CNS/brain lesion, taking as reference smallest sum on study. Unequivocal progression of any CNS/brain lesion nontarget lesions at baseline, or identification of new CNS/brain lesion. DOR was analyzed using the KM methods. RAMD population. As specified in SAP, DOR was to be assessed in RET-fusion CNS metastases sub-population only. Hence only NSCLC arms are presented here. Participants with a CR/PR were assessed for this OM. Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. 9999=upper limit of 95% CI was not estimable due to insufficient number of participants with events. -0.9999=lower limit of 95% CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to approximately 79.8 months
    End point values
    RET- fusion Positive NSCLC With Prior Platinum Treatment RET-fusion Positive NSCLC With Non-platinum Systemic Treatment RET-fusion NSCLC With No Prior Systemic/Platinum Treatment
    Number of subjects analysed
    7
    1
    0 [5]
    Units: months
        median (confidence interval 95%)
    28.3 (10.5 to 9999)
    11.3 (-0.9999 to 9999)
    ( to )
    Notes
    [5] - No participants in this arm exhibited a CR/PR.
    No statistical analyses for this end point

    Secondary: Phase 1: Maximum Plasma Concentration (Cmax)

    Close Top of page
    End point title
    Phase 1: Maximum Plasma Concentration (Cmax) [6]
    End point description
    Pharmacokinetic (PK)-evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. n=number of participants with data available for analysis at the specified timepoint. 9999=Values were LTR for 1 participant. Since data was evaluable only for 1 participant geometric co-efficient of variation was not evaluable. 99999=Since data was available only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    5
    13
    11
    12
    4
    6
    3
    Units: nanograms per milliliters (ng/mL)
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1(n=2,6,5,13,11,12,4,6,3)
    346 ( 9999 )
    335 ( 52.8 )
    198 ( 99.8 )
    459 ( 52.3 )
    688 ( 53.3 )
    1210 ( 85.3 )
    1820 ( 63.8 )
    569 ( 42.0 )
    715 ( 64.1 )
        Cycle 1 Day 15(n=1,6,3,12,9,10,2,5,2)
    130 ( 99999 )
    420 ( 56.9 )
    586 ( 47.8 )
    525 ( 72.5 )
    1390 ( 35.3 )
    1930 ( 66.7 )
    4330 ( 9999 )
    1080 ( 43.8 )
    1780 ( 9999 )
    No statistical analyses for this end point

    Secondary: Phase 1: Time to Maximum Plasma Concentration (Tmax)

    Close Top of page
    End point title
    Phase 1: Time to Maximum Plasma Concentration (Tmax) [7]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. n=number of participants with data available for analysis at the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    5
    13
    11
    12
    4
    6
    3
    Units: hour
    median (full range (min-max))
        Cycle 1 Day 1(n=2,6,5,13,11,12,4,6,3)
    3.04 (2.08 to 4.00)
    2.04 (1.98 to 4.00)
    2.03 (2.00 to 6.03)
    2.07 (0.983 to 7.98)
    2.02 (1.72 to 7.90)
    3.00 (2.00 to 6.03)
    2.00 (2.00 to 2.00)
    12.5 (12.2 to 14.8)
    12.0 (2.07 to 12.3)
        Cycle 1 Day 15(n=1,6,3,12,9,10,2,5,2)
    1.87 (1.87 to 1.87)
    2.00 (1.97 to 4.13)
    3.97 (3.90 to 4.00)
    2.97 (1.05 to 4.08)
    2.23 (0.983 to 24.0)
    3.03 (2.00 to 7.85)
    6.00 (4.00 to 8.00)
    2.00 (0.500 to 3.95)
    4.03 (1.98 to 6.08)
    No statistical analyses for this end point

    Secondary: Phase 1: Time of Last Quantifiable Plasma Drug Concentration (Tlast)

    Close Top of page
    End point title
    Phase 1: Time of Last Quantifiable Plasma Drug Concentration (Tlast) [8]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. n=number of participants with data available for analysis at the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    5
    13
    11
    12
    4
    6
    3
    Units: hours
    median (full range (min-max))
        Cycle 1 Day 1(n=2,6,5,13,11,12,4,6,3)
    24.0 (24.0 to 24.0)
    24.0 (23.1 to 24.4)
    24.0 (7.88 to 24.1)
    24.0 (21.9 to 25.7)
    23.8 (7.88 to 24.0)
    23.8 (22.6 to 24.6)
    23.9 (23.4 to 24.0)
    12.5 (12.2 to 14.8)
    12.3 (12.0 to 14.4)
        Cycle 1 Day 15(n=1,6,3,12,9,10,2,5,2)
    23.8 (23.8 to 23.8)
    24.1 (23.9 to 24.4)
    24.3 (23.6 to 27.8)
    24.0 (8.00 to 26.6)
    24.0 (22.2 to 24.8)
    24.0 (7.38 to 25.4)
    24.1 (24.0 to 24.2)
    12.2 (7.88 to 15.7)
    12.5 (10.1 to 14.8)
    No statistical analyses for this end point

    Secondary: Phase 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC0-24)

    Close Top of page
    End point title
    Phase 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC0-24) [9]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. 9999=Values were LTR for 1 participant. Since data was evaluable only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    24 hours postdose on Day 1 (1 cycle = 28 days)
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    3
    11
    6
    8
    3
    0 [10]
    0 [11]
    Units: hours-nanograms/milliliters(hr-ng/mL)
        geometric mean (geometric coefficient of variation)
    4450 ( 9999 )
    3620 ( 50.8 )
    3010 ( 84.8 )
    5260 ( 46.2 )
    8470 ( 54.5 )
    14700 ( 60.3 )
    27700 ( 94.1 )
    ( )
    ( )
    Notes
    [10] - No participants in this arm were available for PK analysis.
    [11] - No participants in this arm were available for PK analysis.
    No statistical analyses for this end point

    Secondary: Phase 1: Plasma Drug Concentration at 24 Hours Postdose (C24hr)

    Close Top of page
    End point title
    Phase 1: Plasma Drug Concentration at 24 Hours Postdose (C24hr) [12]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint. 9999=Values were LTR for 1 participant. Since data was evaluable only for 1 participant geometric co-efficient of variation was not evaluable. 99999=since data was available only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    3
    11
    9
    8
    3
    0 [13]
    0 [14]
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1 (n=2,6,3,11,6,8,3,0,0)
    110 ( 9999 )
    69.2 ( 81.0 )
    65.8 ( 59.6 )
    104 ( 76.6 )
    221 ( 64.2 )
    376 ( 74.1 )
    715 ( 75.9 )
    ( )
    ( )
        Cycle 1 Day 15 (n=1,6,3,10,9,8,2,0,0)
    55.9 ( 99999 )
    94.2 ( 123 )
    175 ( 31.3 )
    137 ( 132 )
    713 ( 42.2 )
    977 ( 107 )
    1950 ( 9999 )
    ( )
    ( )
    Notes
    [13] - No participants in this arm were available for PK analysis.
    [14] - No participants in this arm were available for PK analysis.
    No statistical analyses for this end point

    Secondary: Phase 1: Apparent Volume of Distribution (Vz/F)

    Close Top of page
    End point title
    Phase 1: Apparent Volume of Distribution (Vz/F) [15]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint. 9999=Values were LTR for 1 participant. Since data was evaluable only for 1 participant geometric co-efficient of variation was not evaluable. 99999=since data was available only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    5
    3
    10
    5
    7
    3
    0 [16]
    0 [17]
    Units: liters
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1(n=2,5,3,10,5,7,3,0,0)
    96.1 ( 9999 )
    230 ( 37.1 )
    458 ( 125 )
    499 ( 50.8 )
    543 ( 82.6 )
    430 ( 62.6 )
    350 ( 115 )
    ( )
    ( )
        Cycle 1 Day 15(1,4,3,9,5,5,1,0,0)
    355 ( 99999 )
    171 ( 176 )
    232 ( 43.7 )
    622 ( 67.3 )
    367 ( 86.6 )
    418 ( 19.9 )
    181 ( 99999 )
    ( )
    ( )
    Notes
    [16] - No participants in this arm were available for PK analysis.
    [17] - No participants in this arm were available for PK analysis.
    No statistical analyses for this end point

    Secondary: Phase 1: Terminal Elimination Half‑life (t½)

    Close Top of page
    End point title
    Phase 1: Terminal Elimination Half‑life (t½) [18]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint. 9999=No participants with data available at the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    5
    3
    10
    5
    7
    3
    0 [19]
    1
    Units: hours
    median (full range (min-max))
        Cycle 1 Day 1 (n=2,5,3,10,5,7,3,0,1)
    16.3 (11.8 to 20.8)
    9.87 (8.98 to 18.3)
    14.3 (8.12 to 31.5)
    12.6 (6.69 to 34.9)
    12.2 (9.53 to 34.5)
    16.5 (10.2 to 48.7)
    19.7 (12.8 to 36.1)
    ( to )
    10.7 (10.7 to 10.7)
        Cycle 1 Day 15(n=1,4,3,9,5,5,1,0,0)
    17.6 (17.6 to 17.6)
    8.10 (5.25 to 39.6)
    13.4 (12.5 to 14.4)
    13.2 (10.1 to 21.8)
    20.4 (9.91 to 27.3)
    20.9 (9.21 to 33.6)
    13.0 (13.0 to 13.0)
    ( to )
    9999 (9999 to 9999)
    Notes
    [19] - No participants in this arm were available for PK analysis.
    No statistical analyses for this end point

    Secondary: Phase 1: Apparent Oral Clearance (CL/F)

    Close Top of page
    End point title
    Phase 1: Apparent Oral Clearance (CL/F) [20]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint. 9999=Values were LTR for 1 participant. Since data was evaluable only for 1 participant geometric co-efficient of variation was not evaluable. 99999=Since data was available only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    3
    10
    9
    8
    3
    0 [21]
    0 [22]
    Units: liters per hour (L/hr)
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1(n=2,5,3,10,5,7,3,0,0)
    4.26 ( 9999 )
    14.7 ( 42.3 )
    20.6 ( 48.1 )
    27.3 ( 60.3 )
    23.3 ( 40.2 )
    15.2 ( 88.1 )
    11.6 ( 81.3 )
    ( )
    ( )
        Cycle 1 Day 15(n=1,6,3,10,9,8,2,0,0)
    14.0 ( 99999 )
    11.3 ( 51.2 )
    12.0 ( 38.9 )
    31.4 ( 97.8 )
    13.2 ( 33.0 )
    11.1 ( 72.2 )
    8.57 ( 9999 )
    ( )
    ( )
    Notes
    [21] - No participants in this arm were available for PK analysis.
    [22] - No participants in this arm were available for PK analysis.
    No statistical analyses for this end point

    Secondary: Phase 1: Accumulation Ratio for Cmax (RCmax)

    Close Top of page
    End point title
    Phase 1: Accumulation Ratio for Cmax (RCmax) [23]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analyzed is the number of participants with data available for analysis. 9999=Since data was available only for 1 participant geometric co-efficient of variation was not evaluable. 99999=Values were LTR for 1 participant. Since data was evaluable only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    24 hours postdose on Day 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    1
    6
    3
    12
    9
    10
    2
    4
    1
    Units: ratio
        geometric mean (geometric coefficient of variation)
    1.04 ( 9999 )
    1.25 ( 27.6 )
    3.20 ( 114 )
    1.17 ( 110 )
    1.87 ( 40.5 )
    1.62 ( 102 )
    2.97 ( 99999 )
    1.91 ( 40.7 )
    1.41 ( 9999 )
    No statistical analyses for this end point

    Secondary: Phase 1: Accumulation Ratio for AUC (RAUC)

    Close Top of page
    End point title
    Phase 1: Accumulation Ratio for AUC (RAUC) [24]
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. 9999=since data was available only for 1 participant geometric co-efficient of variation was not evaluable. 99999=Values were LTR for 1 participant. Since data was evaluable only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    24 hours postdose on Day 15 of Cycle 1 (1 cycle = 28 days)
    Notes
    [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report PK data for Phase I of the study.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    1
    6
    1
    8
    4
    6
    1
    2
    1
    Units: ratio
        geometric mean (geometric coefficient of variation)
    1.43 ( 9999 )
    1.47 ( 11.1 )
    3.22 ( 9999 )
    1.31 ( 147 )
    2.33 ( 11.4 )
    2.75 ( 70.9 )
    2.48 ( 9999 )
    4.28 ( 99999 )
    1.21 ( 9999 )
    No statistical analyses for this end point

    Secondary: Phase 2: Cmax

    Close Top of page
    End point title
    Phase 2: Cmax
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    End point values
    RET- fusion Positive NSCLC Participants Tumor-agnostic Participants RET-altered Solid Tumors Participants RET-mutation Positive Tumors other than MTC Participants
    Number of subjects analysed
    98
    5
    3
    4
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1(n=98,5,0,3,4)
    1680 ( 69.4 )
    1380 ( 65.4 )
    2450 ( 164 )
    1770 ( 87.2 )
        Cycle 1 Day 15(n=87,5,0,3,4)
    2840 ( 50.7 )
    2200 ( 36.7 )
    3440 ( 93.9 )
    2430 ( 55.3 )
    No statistical analyses for this end point

    Secondary: Phase 2: Tmax

    Close Top of page
    End point title
    Phase 2: Tmax
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    End point values
    RET- fusion Positive NSCLC Participants Tumor-agnostic Participants RET-altered Solid Tumors Participants RET-mutation Positive Tumors other than MTC Participants
    Number of subjects analysed
    98
    5
    3
    4
    Units: hours
    median (full range (min-max))
        Cycle 1 Day 1(n=98,5,0,3,4)
    4.00 (1.90 to 23.7)
    3.90 (2.0 to 6.0)
    4.0 (4.0 to 6.0)
    2.05 (2 to 8)
        Cycle 1 Day 15(n=87,5,0,3,4)
    4.00 (1.00 to 8.10)
    5.00 (2.0 to 8.0)
    4.00 (2.00 to 6.00)
    3.05 (2 to 6)
    No statistical analyses for this end point

    Secondary: Phase 2: Tlast

    Close Top of page
    End point title
    Phase 2: Tlast
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    End point values
    RET- fusion Positive NSCLC Participants Tumor-agnostic Participants RET-altered Solid Tumors Participants RET-mutation Positive Tumors other than MTC Participants
    Number of subjects analysed
    98
    5
    3
    4
    Units: hours
    median (full range (min-max))
        Cycle 1 Day 1(n=98,5,0,3,4)
    23.9 (2.40 to 24.8)
    8.00 (7.8 to 23.5)
    23.10 (8.0 to 24.0)
    8.05 (8.0 to 24.0)
        Cycle 1 Day 15(n=87,5,0,3,4)
    23.8 (7.80 to 26.5)
    23.70 (7.9 to 24.0)
    24.00 (7.9 to 24.0)
    24.00 (23.8 to 24.0)
    No statistical analyses for this end point

    Secondary: Phase 2: AUC0-24

    Close Top of page
    End point title
    Phase 2: AUC0-24
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint. 9999=Since data was available only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    End point values
    RET- fusion Positive NSCLC Participants Tumor-agnostic Participants RET-altered Solid Tumors Participants RET-mutation Positive Tumors other than MTC Participants
    Number of subjects analysed
    70
    3
    2
    4
    Units: hr-ng/ mL
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1 (n=70,2,0,1,3)
    20400 ( 64.2 )
    17400 ( 152 )
    103000 ( 9999 )
    18400 ( 69.8 )
        Cycle 1 Day 15(n=50,3,0,2,4)
    40100 ( 59.5 )
    33900 ( 27.4 )
    91100 ( 46.8 )
    32000 ( 90.8 )
    No statistical analyses for this end point

    Secondary: Phase 2: C24hr

    Close Top of page
    End point title
    Phase 2: C24hr
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint.
    End point type
    Secondary
    End point timeframe
    24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    End point values
    RET- fusion Positive NSCLC Participants Tumor-agnostic Participants RET-altered Solid Tumors Participants RET-mutation Positive Tumors other than MTC Participants
    Number of subjects analysed
    92
    5
    3
    4
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1(n=92,5,0,3,3)
    540 ( 75.4 )
    519 ( 197 )
    1020 ( 225 )
    415 ( 140 )
        Cycle 1 Day 15(n=82,5,0,2,4)
    1150 ( 69 )
    797 ( 42.8 )
    1400 ( 207 )
    1050 ( 94.0 )
    No statistical analyses for this end point

    Secondary: Phase 2: t½

    Close Top of page
    End point title
    Phase 2: t½
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint. 9999=since data was available only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    End point values
    RET- fusion Positive NSCLC Participants Tumor-agnostic Participants RET-altered Solid Tumors Participants RET-mutation Positive Tumors other than MTC Participants
    Number of subjects analysed
    57
    2
    1
    3
    Units: hours
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1(n=57,2,0,1,3)
    13.4 ( 44.1 )
    18.4 ( 98.8 )
    20.8 ( 9999 )
    11.0 ( 55.8 )
        Cycle 1 Day 15(n=47,2,0,1,2)
    17.9 ( 58.8 )
    16.5 ( 44.6 )
    25.8 ( 9999 )
    63.0 ( 882 )
    No statistical analyses for this end point

    Secondary: Phase 2: CL/F

    Close Top of page
    End point title
    Phase 2: CL/F
    End point description
    PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Number analysed is the number of participants with data available for analysis. n=number of participants with data available for analysis at the specified timepoint. 9999=since data was available only for 1 participant geometric co-efficient of variation was not evaluable.
    End point type
    Secondary
    End point timeframe
    Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)
    End point values
    RET- fusion Positive NSCLC Participants Tumor-agnostic Participants RET-altered Solid Tumors Participants RET-mutation Positive Tumors other than MTC Participants
    Number of subjects analysed
    47
    2
    1
    3
    Units: liters per hour (L/hr)
    geometric mean (geometric coefficient of variation)
        Cycle 1 Day 1(n=30,2,0,1,3)
    13.4 ( 56.8 )
    12.7 ( 347 )
    2.00 ( 9999 )
    16.1 ( 43.3 )
        Cycle 1 Day 15(n=47,2,0,1,2)
    9.91 ( 58.9 )
    7.49 ( 64.4 )
    2.92 ( 9999 )
    1.39 ( 1220 )
    No statistical analyses for this end point

    Secondary: Phase 1: Percent Change From Baseline in Dual Specificity Phosphatase 6 (DUSP6)

    Close Top of page
    End point title
    Phase 1: Percent Change From Baseline in Dual Specificity Phosphatase 6 (DUSP6) [25]
    End point description
    The dose dependent change in a mitogen-activated protein kinases (MAPK) pathway expression signature was analyzed for all available samples of MTC and NSCLC participants. Participants with archived sample (used as baseline) and on treatment Cycle 2 Day 1 (1 cycle = 28 days) tumor tissues with greater than 20% tumor cells are included in the analysis. The changes in tumor biomarker DUSP6 levels was explored. Safety Population included all participants who have received at least 1 dose of the study drug regardless of starting dose levels. Participants are presented per the planned treatment arm for this endpoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4
    Notes
    [25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report data for Phase I of the study only. Hence, Phase II arm is not included.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    5
    13
    11
    12
    4
    5
    4
    Units: percent change
        arithmetic mean (standard deviation)
    0 ( 0 )
    54.26 ( 88.318 )
    0 ( 0 )
    -20.27 ( 42.971 )
    -74.87 ( 15.707 )
    -13.32 ( 82.394 )
    0 ( 0 )
    -81.57 ( 3.057 )
    -61.96 ( 39.141 )
    No statistical analyses for this end point

    Secondary: Phase 1: Percent Change From Baseline in Sprout Receptor Tyrosine Kinase Signaling Antagonist 4 (SPRY4)

    Close Top of page
    End point title
    Phase 1: Percent Change From Baseline in Sprout Receptor Tyrosine Kinase Signaling Antagonist 4 (SPRY4) [26]
    End point description
    The dose dependent change in a MAPK pathway expression signature was analyzed for all available samples of MTC and NSCLC participants. Participants with archived sample (used as baseline) and on treatment Cycle 2 Day 1 (1 cycle = 28 days) tumor tissues with greater than 20% tumor cells are included in the analysis. The changes in tumor biomarker SPRY4 levels was explored. Safety Population included all participants who have received at least 1 dose of the study drug regardless of starting dose levels. Participants are presented per the planned treatment arm for this endpoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4
    Notes
    [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was planned to report data for Phase I of the study only. Hence, Phase II arm is not included.
    End point values
    Phase I: Pralsetinib 30 mg Phase I: Pralsetinib 60 mg Phase I: Pralsetinib 100 mg Phase I: Pralsetinib 200 mg Phase I: Pralsetinib 300 mg Phase I: Pralsetinib 400 mg Phase I: Pralsetinib 600 mg Phase I: Pralsetinib 100/100 mg Phase I: Pralsetinib 200/100 mg
    Number of subjects analysed
    2
    6
    5
    13
    11
    12
    4
    5
    4
    Units: percent change
        arithmetic mean (standard deviation)
    0 ( 0 )
    210.16 ( 309.468 )
    0 ( 0 )
    -34.98 ( 29.569 )
    -69.00 ( 28.731 )
    -3.26 ( 99.349 )
    0 ( 0 )
    -75.65 ( 10.944 )
    124.93 ( 311.210 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    AEs and SAEs: From Cycle 1 Day 1 up to 30 days after the final dose of study drug (up to approximately 6.7 years) All-cause Mortality: Up to approximately 7 years
    Adverse event reporting additional description
    Safety Population included all participants who have received at least 1 dose of the study drug regardless of starting dose levels. As pre-specified in the SAP, safety data was to be analyzed and reported as per the pre-planned grouped dose level II (SAP section 3.6.5.2). Hence, per dose safety data is not presented for this study.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Pralsetinib ≤ 300 mg QD
    Reporting group description
    Participants received pralsetinib, 300 mg or less, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Pralsetinib All Doses
    Reporting group description
    Participants received pralsetinib at varying doses at the QD and BID schedule until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Pralsetinib BID Dosing Schedule
    Reporting group description
    Participants received pralsetinib, 100 mg, orally, BID or 200 mg in the morning and then 100 mg in the evening, orally, until discontinuation due to toxicity, disease progression, or other reasons.

    Reporting group title
    Pralsetinib 400 mg QD
    Reporting group description
    Participants received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.

    Serious adverse events
    Pralsetinib ≤ 300 mg QD Pralsetinib All Doses Pralsetinib BID Dosing Schedule Pralsetinib 400 mg QD
    Total subjects affected by serious adverse events
         subjects affected / exposed
    26 / 37 (70.27%)
    416 / 590 (70.51%)
    7 / 9 (77.78%)
    381 / 540 (70.56%)
         number of deaths (all causes)
    15
    268
    7
    245
         number of deaths resulting from adverse events
    0
    10
    0
    9
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Diffuse large B-cell lymphoma
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gallbladder cancer
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung cancer metastatic
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
    Anaplastic large-cell lymphoma
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Bone neoplasm
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain neoplasm
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cancer pain
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to bone
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Medullary thyroid cancer
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
    Non-small cell lung cancer
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Neoplasm progression
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Neoplasm malignant
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Metastatic neoplasm
         subjects affected / exposed
    0 / 37 (0.00%)
    7 / 590 (1.19%)
    0 / 9 (0.00%)
    7 / 540 (1.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 7
    0 / 0
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    Metastasis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to liver
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to central nervous system
         subjects affected / exposed
    0 / 37 (0.00%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    6 / 540 (1.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 6
    0 / 0
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung neoplasm malignant
         subjects affected / exposed
    1 / 37 (2.70%)
    27 / 590 (4.58%)
    0 / 9 (0.00%)
    26 / 540 (4.81%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 31
    0 / 0
    0 / 30
         deaths causally related to treatment / all
    0 / 1
    0 / 22
    0 / 0
    0 / 21
    Malignant neoplasm progression
         subjects affected / exposed
    1 / 37 (2.70%)
    5 / 590 (0.85%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 5
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 1
    0 / 4
    0 / 0
    0 / 3
    Malignant pleural effusion
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Paraneoplastic syndrome
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour pain
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour necrosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thyroid cancer metastatic
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    Thyroid cancer
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    Vascular disorders
    Peripheral embolism
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral arterial occlusive disease
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Orthostatic hypotension
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Embolism
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Haematoma
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertension
         subjects affected / exposed
    0 / 37 (0.00%)
    8 / 590 (1.36%)
    0 / 9 (0.00%)
    8 / 540 (1.48%)
         occurrences causally related to treatment / all
    0 / 0
    5 / 9
    0 / 0
    5 / 9
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 4
    0 / 0
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Internal haemorrhage
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Jugular vein thrombosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Peripheral ischaemia
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral vascular disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Phlebitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Superior vena cava syndrome
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Spinal decompression
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Calcinosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 4
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Face oedema
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Drug withdrawal syndrome
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Malaise
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Impaired healing
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Granuloma
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 5
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Fatigue
         subjects affected / exposed
    1 / 37 (2.70%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 5
    0 / 0
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Condition aggravated
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    0 / 37 (0.00%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    6 / 540 (1.11%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 6
    0 / 0
    2 / 6
         deaths causally related to treatment / all
    0 / 0
    2 / 6
    0 / 0
    2 / 6
    Disease progression
         subjects affected / exposed
    0 / 37 (0.00%)
    10 / 590 (1.69%)
    0 / 9 (0.00%)
    10 / 540 (1.85%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 10
    0 / 0
    0 / 10
         deaths causally related to treatment / all
    0 / 0
    0 / 5
    0 / 0
    0 / 5
    Oedema peripheral
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 37 (0.00%)
    15 / 590 (2.54%)
    0 / 9 (0.00%)
    15 / 540 (2.78%)
         occurrences causally related to treatment / all
    0 / 0
    5 / 21
    0 / 0
    5 / 21
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Performance status decreased
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Abnormal uterine bleeding
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Heavy menstrual bleeding
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ovarian cyst
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Prostatitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Uterine polyp
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Epistaxis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    0 / 37 (0.00%)
    10 / 590 (1.69%)
    0 / 9 (0.00%)
    10 / 540 (1.85%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 14
    0 / 0
    1 / 14
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    Cough
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chylothorax
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asphyxia
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    Laryngeal oedema
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute respiratory distress syndrome
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemoptysis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemothorax
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    0 / 37 (0.00%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    6 / 540 (1.11%)
         occurrences causally related to treatment / all
    0 / 0
    9 / 12
    0 / 0
    9 / 12
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
    Acute respiratory failure
         subjects affected / exposed
    0 / 37 (0.00%)
    6 / 590 (1.02%)
    1 / 9 (11.11%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 6
    0 / 1
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 1
    Pneumothorax spontaneous
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    0 / 37 (0.00%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 8
    0 / 0
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis aspiration
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    Pneumonitis
         subjects affected / exposed
    2 / 37 (5.41%)
    29 / 590 (4.92%)
    0 / 9 (0.00%)
    27 / 540 (5.00%)
         occurrences causally related to treatment / all
    3 / 3
    32 / 35
    0 / 0
    29 / 32
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
    Pleural effusion
         subjects affected / exposed
    2 / 37 (5.41%)
    14 / 590 (2.37%)
    1 / 9 (11.11%)
    11 / 540 (2.04%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 15
    0 / 1
    0 / 12
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung consolidation
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    4 / 37 (10.81%)
    12 / 590 (2.03%)
    0 / 9 (0.00%)
    8 / 540 (1.48%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 12
    0 / 0
    0 / 8
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    2 / 37 (5.41%)
    9 / 590 (1.53%)
    1 / 9 (11.11%)
    6 / 540 (1.11%)
         occurrences causally related to treatment / all
    0 / 2
    2 / 10
    0 / 1
    2 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 3
    0 / 1
    0 / 2
    Respiratory distress
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary hypertension
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Mental status changes
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 4
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Delirium
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Confusional state
         subjects affected / exposed
    1 / 37 (2.70%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Product issues
    Device dislocation
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device issue
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Hepatic enzyme increased
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Electrocardiogram QT prolonged
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 37 (0.00%)
    5 / 590 (0.85%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 5
    0 / 0
    4 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood bilirubin increased
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 4
    0 / 0
    3 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bilirubin conjugated increased
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 4
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Inflammatory marker increased
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutrophil count decreased
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphocyte count decreased
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Platelet count decreased
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    15 / 15
    0 / 0
    15 / 15
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Chemical peritonitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 7
    0 / 0
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal compression fracture
         subjects affected / exposed
    1 / 37 (2.70%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seroma
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 7
    0 / 0
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Radiation pneumonitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Procedural pneumothorax
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immunisation reaction
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Periprosthetic fracture
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meniscus injury
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Joint dislocation
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Incisional hernia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis radiation
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wrist fracture
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound dehiscence
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Traumatic haematoma
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal fracture
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Angina pectoris
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stress cardiomyopathy
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pericardial effusion
         subjects affected / exposed
    1 / 37 (2.70%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 5
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Myocardial injury
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardio-respiratory arrest
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Cardiac failure congestive
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac discomfort
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Cardiac arrest
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    Bradycardia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebral infarction
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Cerebral haemorrhage
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral haematoma
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carotid artery stenosis
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ataxia
         subjects affected / exposed
    1 / 37 (2.70%)
    3 / 590 (0.51%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain oedema
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Epilepsy
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    0 / 37 (0.00%)
    5 / 590 (0.85%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 6
    0 / 0
    1 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cognitive disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Migraine
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malignant spinal cord compression
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbar radiculopathy
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intracranial pressure increased
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydrocephalus
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neuralgia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neuropathy peripheral
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vocal cord paralysis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vertebral artery thrombosis
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 37 (0.00%)
    7 / 590 (1.19%)
    0 / 9 (0.00%)
    7 / 540 (1.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 10
    0 / 0
    0 / 10
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Radiculopathy
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Radicular pain
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Presyncope
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Polyneuropathy chronic
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Paraesthesia
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia of malignant disease
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaemia macrocytic
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    1 / 37 (2.70%)
    34 / 590 (5.76%)
    1 / 9 (11.11%)
    32 / 540 (5.93%)
         occurrences causally related to treatment / all
    0 / 1
    33 / 52
    0 / 1
    33 / 50
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood loss anaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disseminated intravascular coagulation
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Eosinophilia
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    0 / 37 (0.00%)
    5 / 590 (0.85%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 0
    5 / 6
    0 / 0
    5 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Leukocytosis
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    62 / 62
    0 / 0
    62 / 62
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bicytopenia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    0 / 37 (0.00%)
    8 / 590 (1.36%)
    0 / 9 (0.00%)
    8 / 540 (1.48%)
         occurrences causally related to treatment / all
    0 / 0
    11 / 11
    0 / 0
    11 / 11
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphopenia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Keratitis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    1 / 9 (11.11%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    0 / 37 (0.00%)
    8 / 590 (1.36%)
    1 / 9 (11.11%)
    7 / 540 (1.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 8
    0 / 1
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal mass
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal distension
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aphthous ulcer
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    2 / 37 (5.41%)
    9 / 590 (1.53%)
    0 / 9 (0.00%)
    7 / 540 (1.30%)
         occurrences causally related to treatment / all
    0 / 2
    4 / 9
    0 / 0
    4 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 37 (2.70%)
    5 / 590 (0.85%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    3 / 7
    0 / 0
    3 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ascites
         subjects affected / exposed
    0 / 37 (0.00%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    6 / 540 (1.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 8
    0 / 0
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Noninfective sialoadenitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    2 / 37 (5.41%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 4
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Melaena
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 37 (0.00%)
    8 / 590 (1.36%)
    1 / 9 (11.11%)
    7 / 540 (1.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 8
    0 / 1
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematochezia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematemesis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal inflammation
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestine perforation
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stomatitis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 4
    0 / 1
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal perforation
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 6
    0 / 0
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumoperitoneum
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 5
    0 / 0
    1 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophagitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    2 / 37 (5.41%)
    7 / 590 (1.19%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 8
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Proctitis ulcerative
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholelithiasis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis chronic
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    1 / 37 (2.70%)
    8 / 590 (1.36%)
    0 / 9 (0.00%)
    7 / 540 (1.30%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 9
    0 / 0
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatic failure
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Cholangitis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bile duct stone
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholangitis acute
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Liver injury
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 4
    0 / 0
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
    Liver disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertransaminasaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperbilirubinaemia
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatic function abnormal
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 4
    0 / 0
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subcapsular hepatic haematoma
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Dermatitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash maculo-papular
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Calculus urinary
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal colic
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    1 / 37 (2.70%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 7
    0 / 0
    2 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Obstructive nephropathy
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract obstruction
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal impairment
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ureterolithiasis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urethral stenosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endocrine disorders
    Hypercalcaemia of malignancy
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adrenal insufficiency
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    2 / 37 (5.41%)
    6 / 590 (1.02%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 6
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 37 (0.00%)
    9 / 590 (1.53%)
    0 / 9 (0.00%)
    9 / 540 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 11
    0 / 0
    0 / 11
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal pain
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myositis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neck pain
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematoma muscle
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Flank pain
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chest wall haematoma
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bone pain
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    0 / 37 (0.00%)
    8 / 590 (1.36%)
    0 / 9 (0.00%)
    8 / 540 (1.48%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 8
    0 / 0
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pathological fracture
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rhabdomyolysis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
    Rotator cuff syndrome
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Arthritis infective
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthritis bacterial
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis perforated
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute sinusitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal infection
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atypical mycobacterial pneumonia
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atypical pneumonia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Coronavirus infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Clostridium difficile colitis
         subjects affected / exposed
    1 / 37 (2.70%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 6
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis infective
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 4
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    1 / 37 (2.70%)
    14 / 590 (2.37%)
    0 / 9 (0.00%)
    13 / 540 (2.41%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 19
    0 / 0
    0 / 18
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    COVID-19
         subjects affected / exposed
    1 / 37 (2.70%)
    17 / 590 (2.88%)
    0 / 9 (0.00%)
    16 / 540 (2.96%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 19
    0 / 0
    0 / 18
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    Bronchopulmonary aspergillosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchitis bacterial
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    1 / 37 (2.70%)
    9 / 590 (1.53%)
    0 / 9 (0.00%)
    8 / 540 (1.48%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 9
    0 / 0
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cystitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterobacter bacteraemia
         subjects affected / exposed
    1 / 37 (2.70%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterococcal bacteraemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epididymitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia bacteraemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia urinary tract infection
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Empyema
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis intestinal perforated
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    3 / 37 (8.11%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 6
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia sepsis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Kidney infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Klebsiella bacteraemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Klebsiella urinary tract infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestine infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymph node tuberculosis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 4
    0 / 0
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemophilus infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis B reactivation
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oropharyngeal candidiasis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenic sepsis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nasopharyngitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis enterococcal
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis bacterial
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    5 / 37 (13.51%)
    94 / 590 (15.93%)
    1 / 9 (11.11%)
    87 / 540 (16.11%)
         occurrences causally related to treatment / all
    0 / 5
    30 / 127
    0 / 1
    29 / 120
         deaths causally related to treatment / all
    0 / 1
    3 / 13
    0 / 0
    2 / 11
    Osteomyelitis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatic abscess
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peritonitis bacterial
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumocystis jirovecii pneumonia
         subjects affected / exposed
    1 / 37 (2.70%)
    6 / 590 (1.02%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 1
    5 / 7
    0 / 0
    5 / 6
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
    Meningitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Pneumonia legionella
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia influenzal
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    1 / 9 (11.11%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia haemophilus
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia cytomegaloviral
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Pneumonia bacterial
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 5
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
    Pneumonia staphylococcal
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psoas abscess
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pseudomembranous colitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Postoperative wound infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia viral
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal tuberculosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Scrotal cellulitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    2 / 37 (5.41%)
    25 / 590 (4.24%)
    3 / 9 (33.33%)
    20 / 540 (3.70%)
         occurrences causally related to treatment / all
    0 / 2
    4 / 30
    0 / 5
    4 / 23
         deaths causally related to treatment / all
    0 / 0
    0 / 5
    0 / 1
    0 / 4
    Septic arthritis staphylococcal
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Streptococcal bacteraemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spontaneous bacterial peritonitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin infection
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinusitis bacterial
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinusitis aspergillus
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal bacteraemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tonsillitis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 4
    0 / 0
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    2 / 37 (5.41%)
    26 / 590 (4.41%)
    1 / 9 (11.11%)
    23 / 540 (4.26%)
         occurrences causally related to treatment / all
    0 / 2
    4 / 43
    0 / 1
    4 / 40
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection bacterial
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection enterococcal
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Varicella
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyperkalaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    0 / 9 (0.00%)
    2 / 540 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypercalcaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Failure to thrive
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Electrolyte imbalance
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 4
    0 / 0
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Decreased appetite
         subjects affected / exposed
    1 / 37 (2.70%)
    5 / 590 (0.85%)
    0 / 9 (0.00%)
    4 / 540 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    3 / 5
    0 / 0
    3 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperuricaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour lysis syndrome
         subjects affected / exposed
    2 / 37 (5.41%)
    3 / 590 (0.51%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    2 / 3
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pseudohyperkalaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    1 / 37 (2.70%)
    10 / 590 (1.69%)
    1 / 9 (11.11%)
    8 / 540 (1.48%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 16
    0 / 1
    2 / 14
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    5 / 590 (0.85%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 8
    0 / 0
    3 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    0 / 9 (0.00%)
    1 / 540 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypocalcaemia
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 5
    0 / 0
    3 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypophosphataemia
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    0 / 9 (0.00%)
    3 / 540 (0.56%)
         occurrences causally related to treatment / all
    0 / 0
    5 / 5
    0 / 0
    5 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Pralsetinib ≤ 300 mg QD Pralsetinib All Doses Pralsetinib BID Dosing Schedule Pralsetinib 400 mg QD
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    36 / 37 (97.30%)
    585 / 590 (99.15%)
    9 / 9 (100.00%)
    536 / 540 (99.26%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Basal cell carcinoma
         subjects affected / exposed
    0 / 37 (0.00%)
    6 / 590 (1.02%)
    1 / 9 (11.11%)
    5 / 540 (0.93%)
         occurrences all number
    0
    9
    1
    8
    Skin papilloma
         subjects affected / exposed
    0 / 37 (0.00%)
    5 / 590 (0.85%)
    1 / 9 (11.11%)
    4 / 540 (0.74%)
         occurrences all number
    0
    8
    2
    6
    Vascular disorders
    Haematoma
         subjects affected / exposed
    0 / 37 (0.00%)
    7 / 590 (1.19%)
    1 / 9 (11.11%)
    6 / 540 (1.11%)
         occurrences all number
    0
    7
    1
    6
    Vasodilatation
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Hypotension
         subjects affected / exposed
    2 / 37 (5.41%)
    15 / 590 (2.54%)
    0 / 9 (0.00%)
    13 / 540 (2.41%)
         occurrences all number
    2
    18
    0
    16
    Intermittent claudication
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Peripheral arterial occlusive disease
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Peripheral vascular disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Thrombosis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Hypertension
         subjects affected / exposed
    9 / 37 (24.32%)
    206 / 590 (34.92%)
    4 / 9 (44.44%)
    189 / 540 (35.00%)
         occurrences all number
    12
    530
    11
    499
    General disorders and administration site conditions
    Peripheral swelling
         subjects affected / exposed
    4 / 37 (10.81%)
    22 / 590 (3.73%)
    1 / 9 (11.11%)
    17 / 540 (3.15%)
         occurrences all number
    5
    25
    1
    19
    Oedema peripheral
         subjects affected / exposed
    9 / 37 (24.32%)
    117 / 590 (19.83%)
    4 / 9 (44.44%)
    104 / 540 (19.26%)
         occurrences all number
    10
    154
    4
    140
    Non-cardiac chest pain
         subjects affected / exposed
    4 / 37 (10.81%)
    27 / 590 (4.58%)
    2 / 9 (22.22%)
    21 / 540 (3.89%)
         occurrences all number
    4
    28
    2
    22
    Mucosal inflammation
         subjects affected / exposed
    3 / 37 (8.11%)
    43 / 590 (7.29%)
    0 / 9 (0.00%)
    40 / 540 (7.41%)
         occurrences all number
    4
    60
    0
    56
    Malaise
         subjects affected / exposed
    0 / 37 (0.00%)
    34 / 590 (5.76%)
    0 / 9 (0.00%)
    33 / 540 (6.11%)
         occurrences all number
    0
    45
    0
    44
    Localised oedema
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences all number
    0
    4
    1
    3
    Fatigue
         subjects affected / exposed
    12 / 37 (32.43%)
    169 / 590 (28.64%)
    2 / 9 (22.22%)
    154 / 540 (28.52%)
         occurrences all number
    17
    309
    2
    289
    Face oedema
         subjects affected / exposed
    1 / 37 (2.70%)
    43 / 590 (7.29%)
    0 / 9 (0.00%)
    42 / 540 (7.78%)
         occurrences all number
    1
    58
    0
    57
    Chills
         subjects affected / exposed
    4 / 37 (10.81%)
    32 / 590 (5.42%)
    0 / 9 (0.00%)
    28 / 540 (5.19%)
         occurrences all number
    4
    34
    0
    30
    Chest discomfort
         subjects affected / exposed
    1 / 37 (2.70%)
    18 / 590 (3.05%)
    1 / 9 (11.11%)
    16 / 540 (2.96%)
         occurrences all number
    1
    21
    1
    19
    Calcinosis
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    2
    2
    0
    Asthenia
         subjects affected / exposed
    1 / 37 (2.70%)
    90 / 590 (15.25%)
    0 / 9 (0.00%)
    88 / 540 (16.30%)
         occurrences all number
    1
    194
    0
    192
    Pyrexia
         subjects affected / exposed
    7 / 37 (18.92%)
    176 / 590 (29.83%)
    3 / 9 (33.33%)
    164 / 540 (30.37%)
         occurrences all number
    11
    286
    7
    266
    Reproductive system and breast disorders
    Breast calcifications
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Erectile dysfunction
         subjects affected / exposed
    2 / 37 (5.41%)
    32 / 590 (5.42%)
    0 / 9 (0.00%)
    30 / 540 (5.56%)
         occurrences all number
    2
    36
    0
    34
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea exertional
         subjects affected / exposed
    1 / 37 (2.70%)
    24 / 590 (4.07%)
    1 / 9 (11.11%)
    22 / 540 (4.07%)
         occurrences all number
    1
    34
    1
    32
    Cough
         subjects affected / exposed
    9 / 37 (24.32%)
    161 / 590 (27.29%)
    2 / 9 (22.22%)
    149 / 540 (27.59%)
         occurrences all number
    11
    236
    2
    222
    Dysphonia
         subjects affected / exposed
    1 / 37 (2.70%)
    49 / 590 (8.31%)
    1 / 9 (11.11%)
    47 / 540 (8.70%)
         occurrences all number
    1
    57
    1
    55
    Dyspnoea
         subjects affected / exposed
    12 / 37 (32.43%)
    127 / 590 (21.53%)
    2 / 9 (22.22%)
    112 / 540 (20.74%)
         occurrences all number
    15
    165
    3
    146
    Epistaxis
         subjects affected / exposed
    2 / 37 (5.41%)
    43 / 590 (7.29%)
    0 / 9 (0.00%)
    41 / 540 (7.59%)
         occurrences all number
    2
    51
    0
    49
    Oropharyngeal pain
         subjects affected / exposed
    4 / 37 (10.81%)
    45 / 590 (7.63%)
    0 / 9 (0.00%)
    41 / 540 (7.59%)
         occurrences all number
    4
    58
    0
    54
    Pleural effusion
         subjects affected / exposed
    2 / 37 (5.41%)
    18 / 590 (3.05%)
    0 / 9 (0.00%)
    16 / 540 (2.96%)
         occurrences all number
    2
    38
    0
    36
    Pneumonitis
         subjects affected / exposed
    7 / 37 (18.92%)
    59 / 590 (10.00%)
    1 / 9 (11.11%)
    51 / 540 (9.44%)
         occurrences all number
    11
    109
    1
    97
    Productive cough
         subjects affected / exposed
    0 / 37 (0.00%)
    36 / 590 (6.10%)
    1 / 9 (11.11%)
    35 / 540 (6.48%)
         occurrences all number
    0
    40
    1
    39
    Rhinorrhoea
         subjects affected / exposed
    1 / 37 (2.70%)
    7 / 590 (1.19%)
    1 / 9 (11.11%)
    5 / 540 (0.93%)
         occurrences all number
    1
    7
    1
    5
    Upper respiratory tract congestion
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Wheezing
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences all number
    0
    4
    1
    3
    Nasal congestion
         subjects affected / exposed
    4 / 37 (10.81%)
    24 / 590 (4.07%)
    1 / 9 (11.11%)
    19 / 540 (3.52%)
         occurrences all number
    4
    27
    1
    22
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    4 / 37 (10.81%)
    32 / 590 (5.42%)
    0 / 9 (0.00%)
    28 / 540 (5.19%)
         occurrences all number
    4
    35
    0
    31
    Depression
         subjects affected / exposed
    2 / 37 (5.41%)
    21 / 590 (3.56%)
    0 / 9 (0.00%)
    19 / 540 (3.52%)
         occurrences all number
    2
    22
    0
    20
    Insomnia
         subjects affected / exposed
    2 / 37 (5.41%)
    52 / 590 (8.81%)
    2 / 9 (22.22%)
    47 / 540 (8.70%)
         occurrences all number
    2
    61
    2
    56
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    16 / 37 (43.24%)
    232 / 590 (39.32%)
    3 / 9 (33.33%)
    212 / 540 (39.26%)
         occurrences all number
    31
    495
    4
    459
    Aspartate aminotransferase increased
         subjects affected / exposed
    17 / 37 (45.95%)
    295 / 590 (50.00%)
    3 / 9 (33.33%)
    273 / 540 (50.56%)
         occurrences all number
    41
    739
    3
    693
    Blood alkaline phosphatase increased
         subjects affected / exposed
    8 / 37 (21.62%)
    78 / 590 (13.22%)
    1 / 9 (11.11%)
    68 / 540 (12.59%)
         occurrences all number
    9
    125
    1
    112
    Blood bilirubin increased
         subjects affected / exposed
    2 / 37 (5.41%)
    61 / 590 (10.34%)
    1 / 9 (11.11%)
    58 / 540 (10.74%)
         occurrences all number
    5
    172
    1
    166
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 37 (0.00%)
    97 / 590 (16.44%)
    0 / 9 (0.00%)
    97 / 540 (17.96%)
         occurrences all number
    0
    445
    0
    445
    Blood creatinine increased
         subjects affected / exposed
    11 / 37 (29.73%)
    158 / 590 (26.78%)
    3 / 9 (33.33%)
    143 / 540 (26.48%)
         occurrences all number
    17
    310
    4
    288
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    0 / 37 (0.00%)
    47 / 590 (7.97%)
    0 / 9 (0.00%)
    47 / 540 (8.70%)
         occurrences all number
    0
    72
    0
    72
    Electrocardiogram QT prolonged
         subjects affected / exposed
    0 / 37 (0.00%)
    32 / 590 (5.42%)
    0 / 9 (0.00%)
    31 / 540 (5.74%)
         occurrences all number
    0
    40
    0
    39
    Electrocardiogram repolarisation abnormality
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 37 (0.00%)
    38 / 590 (6.44%)
    0 / 9 (0.00%)
    38 / 540 (7.04%)
         occurrences all number
    0
    108
    0
    108
    Hepatic enzyme increased
         subjects affected / exposed
    2 / 37 (5.41%)
    5 / 590 (0.85%)
    1 / 9 (11.11%)
    2 / 540 (0.37%)
         occurrences all number
    4
    9
    1
    4
    Lymphocyte count decreased
         subjects affected / exposed
    6 / 37 (16.22%)
    98 / 590 (16.61%)
    1 / 9 (11.11%)
    90 / 540 (16.67%)
         occurrences all number
    18
    379
    3
    345
    Neutrophil count decreased
         subjects affected / exposed
    5 / 37 (13.51%)
    153 / 590 (25.93%)
    1 / 9 (11.11%)
    146 / 540 (27.04%)
         occurrences all number
    16
    558
    1
    539
    Platelet count decreased
         subjects affected / exposed
    3 / 37 (8.11%)
    72 / 590 (12.20%)
    0 / 9 (0.00%)
    67 / 540 (12.41%)
         occurrences all number
    5
    173
    0
    166
    Weight decreased
         subjects affected / exposed
    2 / 37 (5.41%)
    38 / 590 (6.44%)
    0 / 9 (0.00%)
    36 / 540 (6.67%)
         occurrences all number
    2
    52
    0
    50
    Weight increased
         subjects affected / exposed
    2 / 37 (5.41%)
    64 / 590 (10.85%)
    0 / 9 (0.00%)
    62 / 540 (11.48%)
         occurrences all number
    4
    174
    0
    170
    White blood cell count decreased
         subjects affected / exposed
    14 / 37 (37.84%)
    175 / 590 (29.66%)
    2 / 9 (22.22%)
    157 / 540 (29.07%)
         occurrences all number
    41
    636
    3
    579
    Injury, poisoning and procedural complications
    Abdominal injury
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    1
    2
    1
    0
    Fall
         subjects affected / exposed
    1 / 37 (2.70%)
    21 / 590 (3.56%)
    2 / 9 (22.22%)
    18 / 540 (3.33%)
         occurrences all number
    2
    26
    3
    21
    Hip fracture
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Incision site haematoma
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Joint injury
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    3
    2
    1
    Procedural nausea
         subjects affected / exposed
    1 / 37 (2.70%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    1
    2
    1
    0
    Procedural pain
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences all number
    0
    4
    1
    3
    Cardiac disorders
    Left ventricular hypertrophy
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Left ventricular dysfunction
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Nervous system disorders
    Hypoaesthesia
         subjects affected / exposed
    5 / 37 (13.51%)
    40 / 590 (6.78%)
    0 / 9 (0.00%)
    35 / 540 (6.48%)
         occurrences all number
    5
    51
    0
    46
    Dizziness
         subjects affected / exposed
    7 / 37 (18.92%)
    94 / 590 (15.93%)
    2 / 9 (22.22%)
    83 / 540 (15.37%)
         occurrences all number
    9
    115
    2
    101
    Dysgeusia
         subjects affected / exposed
    2 / 37 (5.41%)
    77 / 590 (13.05%)
    0 / 9 (0.00%)
    74 / 540 (13.70%)
         occurrences all number
    4
    102
    0
    97
    Headache
         subjects affected / exposed
    8 / 37 (21.62%)
    110 / 590 (18.64%)
    1 / 9 (11.11%)
    100 / 540 (18.52%)
         occurrences all number
    8
    152
    1
    140
    Memory impairment
         subjects affected / exposed
    1 / 37 (2.70%)
    15 / 590 (2.54%)
    1 / 9 (11.11%)
    13 / 540 (2.41%)
         occurrences all number
    1
    20
    1
    18
    Paraesthesia
         subjects affected / exposed
    0 / 37 (0.00%)
    33 / 590 (5.59%)
    0 / 9 (0.00%)
    33 / 540 (6.11%)
         occurrences all number
    0
    35
    0
    35
    Peripheral sensory neuropathy
         subjects affected / exposed
    0 / 37 (0.00%)
    22 / 590 (3.73%)
    1 / 9 (11.11%)
    21 / 540 (3.89%)
         occurrences all number
    0
    27
    1
    26
    Neuropathy peripheral
         subjects affected / exposed
    4 / 37 (10.81%)
    32 / 590 (5.42%)
    0 / 9 (0.00%)
    26 / 540 (4.81%)
         occurrences all number
    4
    43
    0
    36
    Blood and lymphatic system disorders
    Leukopenia
         subjects affected / exposed
    4 / 37 (10.81%)
    61 / 590 (10.34%)
    1 / 9 (11.11%)
    55 / 540 (10.19%)
         occurrences all number
    11
    239
    1
    226
    Lymphopenia
         subjects affected / exposed
    7 / 37 (18.92%)
    77 / 590 (13.05%)
    2 / 9 (22.22%)
    67 / 540 (12.41%)
         occurrences all number
    29
    359
    8
    321
    Neutropenia
         subjects affected / exposed
    8 / 37 (21.62%)
    135 / 590 (22.88%)
    2 / 9 (22.22%)
    124 / 540 (22.96%)
         occurrences all number
    22
    456
    6
    422
    Thrombocytopenia
         subjects affected / exposed
    3 / 37 (8.11%)
    48 / 590 (8.14%)
    1 / 9 (11.11%)
    44 / 540 (8.15%)
         occurrences all number
    6
    105
    1
    98
    Anaemia
         subjects affected / exposed
    16 / 37 (43.24%)
    310 / 590 (52.54%)
    6 / 9 (66.67%)
    285 / 540 (52.78%)
         occurrences all number
    45
    1168
    15
    1098
    Ear and labyrinth disorders
    Hypoacusis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Eye disorders
    Vision blurred
         subjects affected / exposed
    1 / 37 (2.70%)
    37 / 590 (6.27%)
    1 / 9 (11.11%)
    34 / 540 (6.30%)
         occurrences all number
    1
    52
    1
    49
    Growth of eyelashes
         subjects affected / exposed
    0 / 37 (0.00%)
    5 / 590 (0.85%)
    1 / 9 (11.11%)
    4 / 540 (0.74%)
         occurrences all number
    0
    5
    1
    4
    Eye disorder
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Corneal epithelial microcysts
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    5 / 37 (13.51%)
    74 / 590 (12.54%)
    0 / 9 (0.00%)
    68 / 540 (12.59%)
         occurrences all number
    5
    95
    0
    89
    Abdominal pain upper
         subjects affected / exposed
    1 / 37 (2.70%)
    49 / 590 (8.31%)
    2 / 9 (22.22%)
    46 / 540 (8.52%)
         occurrences all number
    1
    59
    2
    56
    Ascites
         subjects affected / exposed
    1 / 37 (2.70%)
    23 / 590 (3.90%)
    2 / 9 (22.22%)
    19 / 540 (3.52%)
         occurrences all number
    1
    35
    2
    31
    Chronic gastritis
         subjects affected / exposed
    0 / 37 (0.00%)
    5 / 590 (0.85%)
    1 / 9 (11.11%)
    4 / 540 (0.74%)
         occurrences all number
    0
    5
    1
    4
    Constipation
         subjects affected / exposed
    12 / 37 (32.43%)
    255 / 590 (43.22%)
    2 / 9 (22.22%)
    238 / 540 (44.07%)
         occurrences all number
    16
    351
    2
    329
    Diarrhoea
         subjects affected / exposed
    10 / 37 (27.03%)
    207 / 590 (35.08%)
    4 / 9 (44.44%)
    189 / 540 (35.00%)
         occurrences all number
    19
    407
    7
    373
    Dry mouth
         subjects affected / exposed
    2 / 37 (5.41%)
    96 / 590 (16.27%)
    1 / 9 (11.11%)
    92 / 540 (17.04%)
         occurrences all number
    3
    110
    1
    103
    Dyspepsia
         subjects affected / exposed
    3 / 37 (8.11%)
    32 / 590 (5.42%)
    0 / 9 (0.00%)
    29 / 540 (5.37%)
         occurrences all number
    5
    41
    0
    36
    Dysphagia
         subjects affected / exposed
    2 / 37 (5.41%)
    47 / 590 (7.97%)
    1 / 9 (11.11%)
    44 / 540 (8.15%)
         occurrences all number
    2
    53
    1
    50
    Gastritis
         subjects affected / exposed
    0 / 37 (0.00%)
    11 / 590 (1.86%)
    1 / 9 (11.11%)
    10 / 540 (1.85%)
         occurrences all number
    0
    11
    1
    10
    Gastrointestinal wall thickening
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences all number
    0
    4
    1
    3
    Abdominal distension
         subjects affected / exposed
    2 / 37 (5.41%)
    29 / 590 (4.92%)
    0 / 9 (0.00%)
    27 / 540 (5.00%)
         occurrences all number
    2
    35
    0
    33
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 37 (0.00%)
    37 / 590 (6.27%)
    2 / 9 (22.22%)
    34 / 540 (6.30%)
         occurrences all number
    0
    44
    2
    41
    Abdominal discomfort
         subjects affected / exposed
    2 / 37 (5.41%)
    11 / 590 (1.86%)
    0 / 9 (0.00%)
    9 / 540 (1.67%)
         occurrences all number
    2
    13
    0
    11
    Toothache
         subjects affected / exposed
    0 / 37 (0.00%)
    15 / 590 (2.54%)
    1 / 9 (11.11%)
    14 / 540 (2.59%)
         occurrences all number
    0
    16
    1
    15
    Stomatitis
         subjects affected / exposed
    3 / 37 (8.11%)
    37 / 590 (6.27%)
    0 / 9 (0.00%)
    33 / 540 (6.11%)
         occurrences all number
    3
    57
    0
    53
    Paraesthesia oral
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    1 / 9 (11.11%)
    2 / 540 (0.37%)
         occurrences all number
    0
    3
    1
    2
    Nausea
         subjects affected / exposed
    10 / 37 (27.03%)
    126 / 590 (21.36%)
    1 / 9 (11.11%)
    114 / 540 (21.11%)
         occurrences all number
    17
    182
    1
    163
    Mouth ulceration
         subjects affected / exposed
    0 / 37 (0.00%)
    15 / 590 (2.54%)
    2 / 9 (22.22%)
    13 / 540 (2.41%)
         occurrences all number
    0
    19
    2
    17
    Vomiting
         subjects affected / exposed
    7 / 37 (18.92%)
    95 / 590 (16.10%)
    0 / 9 (0.00%)
    88 / 540 (16.30%)
         occurrences all number
    10
    123
    0
    113
    Skin and subcutaneous tissue disorders
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    2 / 37 (5.41%)
    19 / 590 (3.22%)
    1 / 9 (11.11%)
    16 / 540 (2.96%)
         occurrences all number
    4
    25
    1
    20
    Acne
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences all number
    0
    5
    1
    4
    Actinic keratosis
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Alopecia
         subjects affected / exposed
    2 / 37 (5.41%)
    37 / 590 (6.27%)
    0 / 9 (0.00%)
    34 / 540 (6.30%)
         occurrences all number
    2
    40
    0
    37
    Dermatitis acneiform
         subjects affected / exposed
    3 / 37 (8.11%)
    22 / 590 (3.73%)
    2 / 9 (22.22%)
    17 / 540 (3.15%)
         occurrences all number
    3
    23
    2
    18
    Dry skin
         subjects affected / exposed
    3 / 37 (8.11%)
    25 / 590 (4.24%)
    1 / 9 (11.11%)
    21 / 540 (3.89%)
         occurrences all number
    3
    29
    1
    25
    Hyperhidrosis
         subjects affected / exposed
    2 / 37 (5.41%)
    11 / 590 (1.86%)
    0 / 9 (0.00%)
    9 / 540 (1.67%)
         occurrences all number
    2
    12
    0
    10
    Perioral dermatitis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences all number
    0
    4
    1
    3
    Rash
         subjects affected / exposed
    3 / 37 (8.11%)
    61 / 590 (10.34%)
    0 / 9 (0.00%)
    58 / 540 (10.74%)
         occurrences all number
    3
    74
    0
    71
    Rash erythematous
         subjects affected / exposed
    3 / 37 (8.11%)
    8 / 590 (1.36%)
    0 / 9 (0.00%)
    5 / 540 (0.93%)
         occurrences all number
    3
    8
    0
    5
    Rash maculo-papular
         subjects affected / exposed
    0 / 37 (0.00%)
    15 / 590 (2.54%)
    1 / 9 (11.11%)
    14 / 540 (2.59%)
         occurrences all number
    0
    17
    1
    16
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    1 / 37 (2.70%)
    19 / 590 (3.22%)
    1 / 9 (11.11%)
    17 / 540 (3.15%)
         occurrences all number
    1
    23
    1
    21
    Dysuria
         subjects affected / exposed
    1 / 37 (2.70%)
    29 / 590 (4.92%)
    0 / 9 (0.00%)
    28 / 540 (5.19%)
         occurrences all number
    1
    35
    0
    34
    Renal failure
         subjects affected / exposed
    1 / 37 (2.70%)
    10 / 590 (1.69%)
    1 / 9 (11.11%)
    8 / 540 (1.48%)
         occurrences all number
    1
    12
    2
    9
    Urinary incontinence
         subjects affected / exposed
    0 / 37 (0.00%)
    3 / 590 (0.51%)
    1 / 9 (11.11%)
    2 / 540 (0.37%)
         occurrences all number
    0
    3
    1
    2
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    7 / 37 (18.92%)
    100 / 590 (16.95%)
    3 / 9 (33.33%)
    90 / 540 (16.67%)
         occurrences all number
    9
    130
    3
    118
    Back pain
         subjects affected / exposed
    6 / 37 (16.22%)
    95 / 590 (16.10%)
    1 / 9 (11.11%)
    88 / 540 (16.30%)
         occurrences all number
    6
    126
    1
    119
    Muscle spasms
         subjects affected / exposed
    2 / 37 (5.41%)
    46 / 590 (7.80%)
    0 / 9 (0.00%)
    42 / 540 (7.78%)
         occurrences all number
    2
    54
    0
    50
    Muscular weakness
         subjects affected / exposed
    2 / 37 (5.41%)
    21 / 590 (3.56%)
    0 / 9 (0.00%)
    19 / 540 (3.52%)
         occurrences all number
    2
    25
    0
    23
    Myalgia
         subjects affected / exposed
    1 / 37 (2.70%)
    69 / 590 (11.69%)
    0 / 9 (0.00%)
    67 / 540 (12.41%)
         occurrences all number
    1
    123
    0
    121
    Neck pain
         subjects affected / exposed
    2 / 37 (5.41%)
    36 / 590 (6.10%)
    0 / 9 (0.00%)
    34 / 540 (6.30%)
         occurrences all number
    2
    41
    0
    39
    Pain in extremity
         subjects affected / exposed
    6 / 37 (16.22%)
    72 / 590 (12.20%)
    0 / 9 (0.00%)
    66 / 540 (12.22%)
         occurrences all number
    6
    111
    0
    105
    Infections and infestations
    COVID-19
         subjects affected / exposed
    2 / 37 (5.41%)
    66 / 590 (11.19%)
    0 / 9 (0.00%)
    64 / 540 (11.85%)
         occurrences all number
    4
    75
    0
    71
    Cellulitis
         subjects affected / exposed
    1 / 37 (2.70%)
    12 / 590 (2.03%)
    1 / 9 (11.11%)
    9 / 540 (1.67%)
         occurrences all number
    1
    13
    1
    10
    Ear infection
         subjects affected / exposed
    1 / 37 (2.70%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    2 / 540 (0.37%)
         occurrences all number
    1
    4
    1
    2
    Folliculitis
         subjects affected / exposed
    0 / 37 (0.00%)
    7 / 590 (1.19%)
    1 / 9 (11.11%)
    6 / 540 (1.11%)
         occurrences all number
    0
    8
    2
    6
    Wound infection
         subjects affected / exposed
    0 / 37 (0.00%)
    1 / 590 (0.17%)
    1 / 9 (11.11%)
    0 / 540 (0.00%)
         occurrences all number
    0
    2
    2
    0
    Urinary tract infection
         subjects affected / exposed
    5 / 37 (13.51%)
    87 / 590 (14.75%)
    1 / 9 (11.11%)
    80 / 540 (14.81%)
         occurrences all number
    10
    182
    4
    167
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 37 (2.70%)
    53 / 590 (8.98%)
    1 / 9 (11.11%)
    51 / 540 (9.44%)
         occurrences all number
    1
    63
    1
    61
    Skin candida
         subjects affected / exposed
    1 / 37 (2.70%)
    3 / 590 (0.51%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    1
    3
    1
    1
    Sinusitis
         subjects affected / exposed
    3 / 37 (8.11%)
    22 / 590 (3.73%)
    1 / 9 (11.11%)
    18 / 540 (3.33%)
         occurrences all number
    5
    24
    1
    18
    Pneumonia aspiration
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Pneumonia
         subjects affected / exposed
    4 / 37 (10.81%)
    68 / 590 (11.53%)
    0 / 9 (0.00%)
    64 / 540 (11.85%)
         occurrences all number
    4
    111
    0
    107
    Oropharyngeal candidiasis
         subjects affected / exposed
    0 / 37 (0.00%)
    4 / 590 (0.68%)
    1 / 9 (11.11%)
    3 / 540 (0.56%)
         occurrences all number
    0
    4
    1
    3
    Oral candidiasis
         subjects affected / exposed
    2 / 37 (5.41%)
    21 / 590 (3.56%)
    1 / 9 (11.11%)
    17 / 540 (3.15%)
         occurrences all number
    2
    30
    1
    26
    Lower respiratory tract infection
         subjects affected / exposed
    2 / 37 (5.41%)
    7 / 590 (1.19%)
    1 / 9 (11.11%)
    4 / 540 (0.74%)
         occurrences all number
    2
    7
    1
    4
    Influenza
         subjects affected / exposed
    1 / 37 (2.70%)
    15 / 590 (2.54%)
    1 / 9 (11.11%)
    13 / 540 (2.41%)
         occurrences all number
    1
    16
    1
    14
    Fungal foot infection
         subjects affected / exposed
    0 / 37 (0.00%)
    2 / 590 (0.34%)
    1 / 9 (11.11%)
    1 / 540 (0.19%)
         occurrences all number
    0
    2
    1
    1
    Bronchitis
         subjects affected / exposed
    1 / 37 (2.70%)
    25 / 590 (4.24%)
    1 / 9 (11.11%)
    23 / 540 (4.26%)
         occurrences all number
    2
    31
    1
    28
    Metabolism and nutrition disorders
    Hypoalbuminaemia
         subjects affected / exposed
    5 / 37 (13.51%)
    89 / 590 (15.08%)
    0 / 9 (0.00%)
    84 / 540 (15.56%)
         occurrences all number
    6
    234
    0
    228
    Dehydration
         subjects affected / exposed
    2 / 37 (5.41%)
    12 / 590 (2.03%)
    0 / 9 (0.00%)
    10 / 540 (1.85%)
         occurrences all number
    2
    14
    0
    12
    Hypercalcaemia
         subjects affected / exposed
    2 / 37 (5.41%)
    24 / 590 (4.07%)
    1 / 9 (11.11%)
    21 / 540 (3.89%)
         occurrences all number
    3
    36
    1
    32
    Hyperglycaemia
         subjects affected / exposed
    2 / 37 (5.41%)
    39 / 590 (6.61%)
    0 / 9 (0.00%)
    37 / 540 (6.85%)
         occurrences all number
    2
    61
    0
    59
    Hyperkalaemia
         subjects affected / exposed
    3 / 37 (8.11%)
    33 / 590 (5.59%)
    1 / 9 (11.11%)
    29 / 540 (5.37%)
         occurrences all number
    3
    54
    1
    50
    Hyperphosphataemia
         subjects affected / exposed
    4 / 37 (10.81%)
    109 / 590 (18.47%)
    3 / 9 (33.33%)
    101 / 540 (18.70%)
         occurrences all number
    4
    186
    4
    177
    Decreased appetite
         subjects affected / exposed
    6 / 37 (16.22%)
    124 / 590 (21.02%)
    3 / 9 (33.33%)
    113 / 540 (20.93%)
         occurrences all number
    6
    175
    3
    164
    Hypocalcaemia
         subjects affected / exposed
    7 / 37 (18.92%)
    138 / 590 (23.39%)
    1 / 9 (11.11%)
    130 / 540 (24.07%)
         occurrences all number
    12
    336
    3
    321
    Hypomagnesaemia
         subjects affected / exposed
    4 / 37 (10.81%)
    58 / 590 (9.83%)
    0 / 9 (0.00%)
    54 / 540 (10.00%)
         occurrences all number
    5
    110
    0
    105
    Hyponatraemia
         subjects affected / exposed
    5 / 37 (13.51%)
    79 / 590 (13.39%)
    3 / 9 (33.33%)
    70 / 540 (12.96%)
         occurrences all number
    5
    135
    6
    122
    Hypophosphataemia
         subjects affected / exposed
    6 / 37 (16.22%)
    84 / 590 (14.24%)
    3 / 9 (33.33%)
    75 / 540 (13.89%)
         occurrences all number
    16
    151
    4
    131
    Hypokalaemia
         subjects affected / exposed
    4 / 37 (10.81%)
    103 / 590 (17.46%)
    1 / 9 (11.11%)
    98 / 540 (18.15%)
         occurrences all number
    19
    185
    3
    163

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    09 Jan 2017
    The following changes were made as per amendment 1: The inclusion criteria included only participants with unresectable disease; The exclusion criteria excluded participants with NSCLC with a targetable mutation in estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), or ROS1; An enrollment stopping rule was incorporated that terminated further enrollment to the study if there was an excess of permanent treatment discontinuations due to study drug-related AEs; Strong inhibitors of cytochrome P450 family 1 subfamily A polypeptide 2 (CYP1A2), cytochrome P450 family 2 subfamily D member 6 (CYP2D6), and cytochrome P450 family 3 subfamily A member 4 (CYP3A4), as well as inducers of CYP3A4 and strong dual permeability glycoprotein (P-gp) and CYP3A4 inhibitors were included in the list of prohibited medications; An electrocardiogram (ECG) measurement was added at Day 1 and Day 15, 4 hours post-dose.
    02 Feb 2018
    The following change was made as per amendment 2: Exclusion criterion 1 was revised to exclude NSCLC participants with known BRAF mutations.
    25 Jul 2018
    The following changes were made as per amendment 4.1: Based on the favorable tolerability and encouraging efficacy observed in Phase 1, the sample size of Phase 2 was increased; A summary of Phase 1 was added, including determination of the MTD, overall safety, and preliminary efficacy for Phase 1; The overall enrollment for Phase 2 was increased to further evaluate the safety, efficacy, and PK of pralsetinib in RET-altered patients treated at the MTD/RP2D; Group 6 was added in Phase 2 to assess pralsetinib safety and efficacy in paarticipants previously treated with a selective RET inhibitor; The allowed eastern cooperative oncology group (ECOG) performance status was changed to be 0 to 1; Quality of life assessments added.
    12 Dec 2018
    The following changes were made as per amendment 7: Phase 2: -Definitions of Groups 1 to 4 were adjusted to reflect previous treatment with approved standard of care agents. -Group 5 was split into new Group 5 and new Group 7 to reflect that solid tumor participants with RET fusions and RET mutations may be distinct clinical and/or regulatory populations; Phase 2: - Sample size was 80 participants in Group 1, 40 participants in Group 2, 60 participants in Group 3, and 40 participants in Group 5 to test the efficacy hypotheses for each group (increasing the study’s total sample size to 360 participants); Phase 2: - Safety Review Committee was added; Two new exclusion criteria were added to exclude participants with Grade 2 or serum phosphorus at baseline or with clinically significant interstitial lung disease or interstitial pneumonitis and exclusion criterion 7 was revised to clarify the washout period duration.
    03 Jul 2019
    The following changes were made as per amendment 9: The study phase was updated from “1” to “1/2” to better describe the study design with the increased participant population and hypothesis testing; The Phase 2 Group 2 sample size was increased to 200 participants due to the encouraging initial data in treatment naïve RET fusion-positive NSCLC participants, to allow for enrollment of RET fusion-positive NSCLC participants with no prior treatment (increasing the study’s total sample size to 527); Clarification was added that participants enrolled in Phase 1 and treated at the RP2D were pooled together with the appropriate Phase 2 groups for analyses; Statistics section was updated to align with the SAP.
    08 Jul 2020
    The following changes were made as per amendment 13: Group 5: To more accurately characterize the activity of pralsetinib across various RET fusion-positive solid tumor types, the sample size of Group 5 has increased from N ~ 40 to N ~ 100 participants (increasing the study's total sample size to 647 participants); Phase 2 secondary objective in NSCLC participants and exploratory objective in participants with tumor types other than NSCLC have been updated to assess brain metastases activity in participants with measurable (target by RECIST v1.1) lesions in the brain by BICR (brain metastases sub-population) and assess the time to intracranial progression in all participants; An additional analysis population, the RET-altered Measurable Disease Population, was added to provide an assessment of the activity of pralsetinib in a mechanistically relevant population. This will be the primary analysis population for ORR, DOR, CBR and DCR, while the remaining efficacy endpoints will be examined using the Efficacy Population; Pharmacodynamic parameters of pralsetinib included changes in tumor/blood including, but not limited to, changes in blood calcitonin and CEA and biochemical response rate (MTC participants only); Group 2: The primary intent of this cohort was to assess the activity of pralsetinib in the treatment-naïve participants with NSCLC; therefore, text was added to clarify that this group will include no more than 30 participants with prior systemic therapy; Updated study visit frequency after Cycle 17, all study visits after Cycle 17 will occur at every 4 cycles (16 weeks) (e.g. Cycle 21, Cycle 25…).
    28 May 2022
    The following changes were made as per amendment 14: End of study and duration of participant participation was added; Detail was provided regarding reporting of serious adverse events and reference safety information document.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:12:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA